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1Chapter 1. General introduction
With around 1350 patients in the Netherlands, over 38.000 patients in
Europe, and more than 70.000 patients worldwide (in 2013), cystic fibrosis
(CF) is the most common life threatening genetic disease [1].
1.1 Pathogenesis
Cystic fibrosis is caused by a mutation in the gene encoding for the CF-
transmembrane conductance regulator (CFTR) protein, which is involved
in the transport of chloride ions across the cell membrane [2, 3]. Therefore,
CF is characterized by impaired or absent chloride ion transport, which
affects both absorptive and secretory processes. Today, more than 1900
CFTR mutations are identified, but the functional alterations of only a
small number of these mutations is understood. In general, 6 classes of
mutations can be identified. Class I mutations result in no CFTR protein
formation, class II mutations in a defect in protein traffic to the cell surface,
class III mutations in no function of the protein, class IV in less function of
the protein, class V in less formation of the protein, and class VI in reduced
stability of the protein. Most common is the class II mutation F508del in
which phenylalanine at position 508 is absent [4].
Although CF is a multisystem disease, it is mainly characterized by
digestive disorders (pancreatic insufficiency and intestinal obstruction) and
severe, pulmonary complications. The decreased ion transport results in
less water content in the airway surface liquid, which leads to thick mucus
that is resistant to removal. This impaired mucociliary clearance results in
an inability to effectively clear bacteria [5] and subsequently to chronic air-
way infections, oxidative stress, and chronic airway inflammation. Briefly,
the chronic presence of pathogens in the lung lead to an intense and com-
plex inflammatory reaction with excessive production of chemokines and
pro-inflammatory cytokines, such as interleukin 6 and 8 (IL-6 and IL-8)
and tumor necrosis factor alpha (TNFα) [6], resulting in destruction of the
airway walls and the formation of scar tissue, called fibrosis [7, 8]. Finally,
destruction of the airways will occur with declined lung function (figure
1.1), which is primarily responsible for the morbidity, and for at least 80%
of CF related deaths [9, 10]. Therefore, the main goal of CF treatment
is currently focused on prevention and reduction of airway infection and
inflammation. Besides this, CF care focusses on optimizing the nutrition
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status, physical condition, and quality of life of the patient.
Figure 1.1: Schematic representation of the cystic fibrosis (CF) pathogenesis in the
lung. A defective CFTR gene causes a defect in CFTR protein, abnormal Cl− transport
across the cell membrane, mucus obstruction, inflammation and subsequently bacterial
infection leading to severe loss of lung function. CFTR; cystic fibrosis transmembrane
conductance regulator, ASL; airway surface liquid, ENaC; epithelial Na+ channel. Figure
adapted from Amaral et al. [4].
1.2 Respiratory infections
As mentioned above, respiratory colonizations or infections are the main
problem in CF lung disease. Using the words “colonization” or “infection”
is controversial in CF. “Colonization” is often used to describe the presence
of the pathogen but absence of overt illness, while “infection” is often used
when clinical symptoms, as a result of the pathogens presence, are evident.
Since inflammation is often present in CF patients, it is difficult to deter-
mine whether this inflammation is a result of the presence of the pathogen
or not. Therefore, in this thesis, we will use the term “infection” for “the
acquisition of the pathogen by the host” [11], regardless of whether overt
symptoms are present or not.
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1.2.1 Common pathogens
Although the lungs of children with CF are healthy and normal in appear-
ance directly after birth, soon respiratory infections develop [9]. Rapid
infection with Haemophilus influenzae (H. influenzae) or Staphylococcus
aureus (S. aureus) is typically seen in CF infants.
Figure 1.2: Prevalence of pulmonary infection in CF patients. Pseudomonas aerug-
inosa, Haemophilus influenzae, Burkholderia cepacia complex, Staphylococcus aureus,
Methicillin-resistant Staphylococcus aureus (MRSA), Achromobacter, Stenotrophomonas
maltophilia, and multidrug-resistant Pseudomonas aeruginosa (MDR-PA). Adapted from
the 2014 Annual Data Report of the Cystic Fibrosis Foundation Patient Registry [12].
Haemophilus influenzae and S. aureus are both bacteria often found
in children with CF. Haemophilus influenzae, a gram-negative, facultative
anaerobic bacterium, infects CF patients early in childhood at 1 - 5 year
of age [13]. Although the role of H. influenzae in infection and inflamma-
tion in patients with CF has not been clearly demonstrated, it is evident
that this pathogen is capable of causing exacerbation in CF, which should
be treated with appropriate antibiotics [14]. Staphylococcus aureus is a
gram-positive coccal bacterium which is a frequent cause of pulmonary in-
fection, mainly in infants and children [15-17]. Although the long-term
consequences of infection with S. aureus are found to be less dangerous
than those of pathogens such as P. aeruginosa, the consequences of chronic
S. aureus infection may still lead to considerably reduction of lung function
[18].
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Pseudomonas aeruginosa (P. aeruginosa) is a gram-negative bacterium
which is most feared by CF patients. Especially chronic pulmonary infec-
tions with P. aeruginosa, one of the most important respiratory pathogens
in CF, cause morbidity and mortality in CF patients [13, 19, 20]. Initially,
P. aeruginosa grows as a non-mucoid strain. However, over time, P. aerug-
inosa will form biofilms [21]. These biofilms are very difficult to clear with a
local innate immune response or regular (aggressive) antibiotic treatment,
especially in immune-compromised patients such as CF patients. Pseu-
domonas aeruginosa is known for its ability to adapt to the CF airways,
resulting in phenotypically diverse subpopulations, which are extremely
persistent [22]. Therefore, P. aeruginosa is responsible for around 25% of
the lung infections in paediatric CF, up to 80% of the infections in adult
CF patients [23].
Other common bacteria in CF patients are Stenotrophomonas mal-
tophilia (S. maltophilia), Burkholderia cepacia complex (B. cepacia com-
plex) and methicillin-resistant Staphylococcus aureus (MRSA) (figure 1.2).
Besides these bacteria, other organisms, such as non-tuberculous mycobac-
teria (NTM) are being reported frequently [23], and also fungal infections
are often found in CF airways. The prevalence of the most common fun-
gus, Aspergillus fumigatus (A. fumigatus), varies between 9 and 57% [24-
30]. The majority of patients appear not to have clinical symptoms as a
result of A. fumigatus infection, but only transiently have this organism
in the lungs. However, recent studies show that patients colonized with
both A. fumigatus and P. aeruginosa have a significant reduction of lung
function, and a higher exacerbation and hospitalization rate compared to
patients only infected with P. aeruginosa [31, 32], which increases the need
for detection and eradication of this pathogen.
1.2.2 Current detection of respiratory infections
Fortunately, median life expectancy of CF patients has increased over the
past few decades to 37 years of age [9]. This is a result of more aggressive an-
tibiotic treatment, more specialized care, dedicated CF centres, but mainly
because of earlier diagnosis of respiratory infections. Early recognition and
treatment of respiratory infections are crucial for optimal prognosis in pa-
tients with CF. The currently most used method to detect the presence of
respiratory pathogens is a sputum culture. However; this is an unpleas-
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ant procedure and young patients are often not able to expectorate an
adequate sample. Alternative methods are invasive (bronchoscopy), non-
specific (chest-X-ray) [33], or unreliable (cough swab) [34, 35], and therefore
detection of early infections is not easy. For this reason, there is an urgent
need for a reliable and child-friendly method for detecting early infections.
1.3 Volatile Organic Compound (VOC) analysis
Breath analysis is an attractive upcoming field of medical diagnostics. Clear
advantages of breath analysis as a diagnostic tool are: non-invasive char-
acter, safety and ease of sample collection. It is well known that micro-
organisms produce volatile organic compounds (VOCs) as a consequence
of different metabolic processes, and measurements of VOCs in exhaled
breath might be an alternative method to diagnose infections for clinical
purpose. Results from previous studies have shown the possibility of us-
ing breath tests as indicator for the presence of pathological processes in
the human body. For example, the detection of elevated concentrations of
nitric oxide (NO) in exhaled breath of asthma patients is used to signal in-
flammation of the airways [36-38]. Though, since exhaled breath is a rather
complex mixture of large numbers of compounds, a specific biomarker or
biomarker combination, is essential to successfully use VOCs as a non-
invasive tool for the detection of infections. Furthermore, extremely high
sensitivity of the detection method is needed to be able to detect the low
VOC concentrations up to 1:109 (parts-per-billion by volume) in exhaled
breath.
There is a wide variety of methods available for the detection of breath
compounds ranging from gas chromatography combined with mass spec-
trometry (GC-MS), other MS-based methods [39], chemiluminescence [40,
41], and electronic sensors (eNose) [40, 42, 43] to various laser-based tech-
niques [44, 45], which all have their own advantages and disadvantages. In
the following paragraphs several detection methods will be discussed.
1.3.1 Mass Spectrometry (MS) - based methods
Gas chromatography - mass spectrometry is the current golden standard
for detection of VOCs in exhaled breath [46]. Gas chromatography, which
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can separate compounds in a complex gas mixture, is combined with mass
spectrometry, to identify the different gasses present in the sample. This
technique is often connected to a thermal desorption (TD) unit to pro-
vide preconcentration of the sample, necessary for detecting the very low
concentrations of VOCs in breath [47]. For this preconcentration step,
collection of the breath sample in a suitable bag (e.g. Tedlar® bag) is
necessary. Adsorbent tubes filled with Tenax® TA or even multiple beds
of sorbent material are used to trap the analytes. By heating the sorbent
tube, compounds are released and then enter the GC system and subse-
quently reach the mass spectrometer (see figure 1.3). In order to improve
the performance of traditional GC-MS, the technique can be extended to
2 dimensional GC (GCxGC) for higher separation resolving power, and/or
time of flight (TOF) mass spectrometry for high resolution accurate mass
data [48]. Though, despite its high sensitivity and the possibility to de-
tect multiple compounds at the same time, using GC-MS for VOC analysis
has several disadvantages. The detectable mass to charge (m/z ) range of
GC-MS is typically between 30-500 Da. Detection of small molecules, such
as ammonia and hydrogen cyanide for example, is cumbersome due to the
small m/z range and its dissociation into a few atoms under electron ion-
ization. Furthermore, breath sampling and preconcentration steps prior to
the analysis of the compounds are time consuming, and may lead to signif-
icant losses of compounds, or contamination of the sample [46, 49]. Other
disadvantages are: need for trained personnel, costly equipment with high
maintenance costs, and no direct findings during the consultation.
An alternative that mostly not requires sample preconcentration steps
is proton transfer reaction - mass spectrometry (PTR-MS). This is a soft
ionization technique that uses gas phase H3O
+ ions to ionize VOCs, which
are subsequently separated using a quadrupole mass filter based on their
m/z ratio. Measurements with PTR-MS can be performed fast and on-line,
interesting for real-time measurements in exhaled breath. However, since
characterization of the compounds is performed only according to the m/z
ratio, direct identification is not always possible [46]. Another technology
for VOC detection is selected ion flow tube - mass spectrometry (SIFT-
MS). This technique combines fast flow tube technology and quantitative
mass spectrometry. Briefly, different precursor ions (H3O
+ , NO+ and O2)
are generated in the system and VOCs present in the sample can react with
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Figure 1.3: Schematic representation of gas chromatography - mass spectrometry (GC-
MS) combined with thermal desorption unit. 1: For preconcentration, breath is collected
in a suitable bag and subsequently trapped on adsorbent tubes filled with sorbent material
(e.g. Tenax®). 2: Tenax tube containing breath compounds is heated in a thermal
desorption unit to release the trapped compounds which then enter the GC system and
subsequently reach the mass spectrometer.
one of the chosen precursor ions, producing characteristic ions, which can
be identified and quantified with a quadrupole mass spectrometer and ion
counting system [50]. Main advantages of this technique are that it analyses
samples with high sensitivity, in real-time, without sample preparation [39,
50]. However, compared to GC-MS, this technique has reduced chemical
resolution [51, 52].
1.3.2 Electronic nose (eNose)
Electronic sensors or electronic noses (eNoses) represent a technique that
can distinguish VOC samples based on pattern recognition, like a human
nose can distinguish different smells without knowing what exact com-
pounds are in it. eNoses consist of an array of sensors which together form
a pattern of sensor signals. This pattern or electronic fingerprint encodes
the global composition of a sample [53]. eNoses can be cheap, quick and
easy to use but disadvantages are reproducibility problems, negative effects
of humidity on the sample, competition for sites on the sensor surface, and
inability to identify individual compounds [54, 55].
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1.3.3 Laser-based methods
Laser absorption spectroscopy is mainly used for the detection of only one or
a few compounds in samples. This technique is based on the absorption of
light by VOCs in the sample. Each molecule has its own unique absorption
fingerprint; laser light is absorbed by the molecule only at very specific
wavelengths. Using a laser source at this specific wavelength, mostly in the
infra-red region, selective detection in complex gas mixtures can be achieved
[44, 56, 57]. By measuring the absorbance, one can quantify the compound
of interest, using a standard mixture for calibration of the system. Up till
now, many different laser spectroscopic techniques have been described for
VOC detection in biological samples, such as cavity ring down spectroscopy,
cavity enhanced absorption spectroscopy, and laser-based photo-acoustic
spectroscopy [44, 56-58]. In this thesis, photo-acoustic spectroscopy is used
for the detection of hydrogen cyanide (HCN) and ammonia (NH3). This
spectroscopic approach is based on the conversion of light into sound [59].
Briefly, when the sample gas absorbs laser light, the temperature of the gas
increases; the gas expands thereby increasing the pressure. Blocking the
laser light will decrease the pressure again. By modulating the light with
an audio frequency, pressure variations can be detected with a microphone
(figure 1.4). Advantages of laser-based methods compared to other methods
are the high specificity, high sensitivity, the ability to measure in real-time,
and the potential to make a compact sensor with low maintenance; all
desired for a medical instrument. However, at present, laser absorption
spectroscopy is only suitable for smaller molecules, and is not suitable for
the screening of large numbers of compounds at the same time [60].
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Figure 1.4: Laser-based photo-acoustic spectroscopy - when the sample gas absorbs
laser light, the temperature of the gas increases; the gas expands increasing the pressure.
Pressure variations can be detected by a photoacoustic sensor, i.e. a microphone.
1.4 Potential biomarkers
Breath contains more than 800 volatile compounds [61]. Some of them are
small inorganic compounds such as oxygen, nitric oxide or carbon dioxide,
others are organic compounds such as isoprene, acetone, alcohols, as well as
alkanes [62]. In order to detect respiratory infections in exhaled breath of
CF patients, one needs to identify potential biomarker compounds, specif-
ically produced by the pathogen of interest, and preferably not normally
present in exhaled breath of healthy people. In order to identify such
biomarkers, a number of studies have been published that report on the
production of VOCs by cultures of CF-related pathogens in vitro. Bos
et al. provide in a review paper an overview of VOCs produced by six
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pathogenic bacteria, including P. aeruginosa and S. aureus [63], and report
that those bacteria are able to produce a large variety of compounds, such
as hydrocarbons, alcohols, acids, aldehydes, ketones, cyclic compounds, es-
ters, S-containing and N-containing compounds. In vitro studies are useful
in order to identify potential biomarker compounds, and to study those
compounds in more detail to get better insight in production mechanisms.
However, since VOC production in vitro is found to be dependent on nutri-
tional environment, growth phase and strain [64-69], one can argue that it is
difficult to translate those results to the in vivo situation (the lung environ-
ment) [70]. Therefore, it is necessary to confirm those in vitro biomarkers
in vivo.
Pseudomonas aeruginosa
For detecting the presence of P. aeruginosa, HCN is the most studied
biomarker compound. Pseudomonas aeruginosa is one of a limited number
of organisms that can synthesize cyanide [71]. Hydrogen cyanide has been
identified in the headspace of P. aeruginosa cultured in planktonic as well
as in biofilm conditions [72-75], in sputum samples [19, 76], and in exhaled
breath of P. aeruginosa infected patients, using SIFT-MS [77-79]. Differ-
ent P. aeruginosa strains are found to produce different levels of HCN [73],
and since only low concentrations can be found in exhaled breath of healthy
subjects [80], hydrogen cyanide is identified as a true marker for P. aerug-
inosa infection [81]. Alternative potential markers for P. aeruginosa in
vitro are reported as well, such as 2-nonanone [82], 2-aminoacetophenone
[83], 1-undecene [63, 66, 84-86], 2-butanone [63, 66, 84, 85], 2-4-dimethyl-1-
heptane [63], 4-methyl-quinazonline [63], and methyl thiocyanate [63, 87].
However, little in vivo data is available on these compounds. A study de-
tecting 2-nonanone in sputum headspace of CF and non-CF bronchiectasis
patients, infected and non-infected with P. aeruginosa, showed that this
compound was a marker for P. aeruginosa with a sensitivity of 72% and a
specificity of 88%. But, until now, studies detecting 2-nonanone in exhaled
breath of P. aeruginosa infected and non-infected patients have not been
published yet. 2-Aminoacetophenone, another potential biomarker, has
been studied in exhaled breath using GC-MS. Results show significantly
higher levels in P. aeruginosa infected compared to non-infected CF pa-
tients (p < 0.001) [83]. However, since 2-aminoacetophenone is present in
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food products as well, it is not likely that this compounds will be an ideal
breath biomarker compound [88]. Methyl thiocyanate has been studied in
exhaled breath of P. aeruginosa infected and non-infected CF patients but
no statistical difference was found between the two groups [87]. So far, 1-
undecene, 2-butanone, 2-4-dimethyl-1-heptane and 4-methyl-quinazonline
have not been reported in vivo.
Staphylococcus aureus
Up till now, potential markers for S. aureus detection in vitro are reported
to be isovaleric acid and methylbutanal [63, 66]. Other compounds found
the be elevated in S. aureus headspace are ammonia, methanol, acetalde-
hyde, ethanol, propanol and pentanal [89], as well as butanol, acetone and
acetic acid [90]. Studies investigating the VOC emission of sputum as well
as in vivo studies on compounds in exhaled breath of S. aureus infected
CF patients have not been published yet.
Aspergillus fumigatus
For detecting the presence of A. fumigatus, 2-pentylfuran is reported as a
potential biomarker. It is found in headspace of A. fumigatus cultures and
in exhaled breath of CF patients infected with A. fumigatus [91, 92]. Based
on 2-pentylfuran in exhaled breath, A. fumigatus can be detected with a
sensitivity and specificity of 77 and 78% respectively [91]. However, not all
studies analyzing VOCs in the headspace of A. fumigatus samples detect
2-pentylfuran [93], which raises the question whether this compound is re-
ally promising as a breath biomarker. Besides 2-pentylfuran, high levels
of 3-octanone, isoamyl alcohol, ethanol, cyclohexanone [94], ammonia and
organosulphur compounds are reported in in vitro cultures of A. fumigatus
[64], as well as terpenes such as α-pinene, camphene, limonene, α-18 berg-
amotene and β-trans-bergamotene [68]. Though, these compounds have not
been confirmed by in vivo studies, in which VOCs are analyzed in exhaled
breath of A. fumigatus infected CF patients. One study by Koo et al. has
been performed in patients with invasive aspergillosis, and report that de-
tection of α- trans-bergamotene, β-trans-bergamotene, a β-vatirenene-like
sesquiterpene or trans-geranylacetone identied those patients with 94% sen-
sitivity and 93% specificity [95]. Another recent study showed detection of
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A. fumigatus in exhaled breath of CF patients with 78% sensitivity and
94% specificity, using eNose technology. However, as described earlier, this
technique does not identify individual compounds [96].
Biomarker combinations
Although the detection of specific respiratory pathogens based on one sin-
gle biomarker would be most ideal, it may be that combinations of dif-
ferent volatiles, so-called biomarker combinations, breath prints or VOC
fingerprints, are needed. Different in vitro studies have been performed to
determine these pathogen-specific biomarker combinations, which are of-
ten identified using dedicated multivariate data-analysis strategies, such as
principal component analysis (PCA) and partial least squares discriminant
analysis (PLS-DA) [69, 97-99]. Those studies report to be successfully able
to identify pathogen specific biomarker combinations in vitro to discrim-
inate different pathogens from each other, typically specifying between 5
and 25 compounds needed for good discrimination [48, 64, 70, 89, 90, 94,
99-101]. However, little in vivo data on these biomarker combinations is
available. Only one study by Robroeks et al. is reporting on the discrimina-
tion between infected and non-infected CF patients based on VOC analysis.
By using 14 compounds in exhaled breath, 100% of CF patients with and
without a P. aeruginosa infection were correctly classified [102]. Yet, the
identity of those 14 compounds is not published.
Overall, the knowledge on VOC biomarkers production by different CF-
related pathogens is still limited. Multiple in vitro studies report on VOCs,
but since all use different strains, media, and culturing- and sampling meth-
ods, it is hard to compare the results. Furthermore, in vivo data on most of
the in vitro identified compounds is lacking, making it difficult to evaluate
the clinical potential of these compounds as a breath biomarker to detect
respiratory infections in CF patients.
1.5 Aim and outline of this thesis
The aim of this thesis was to study and identify potential biomarkers in vitro
and in vivo for detection of respiratory pathogens in the lung of CF patients.
Therefore, we studied the VOC emission from reference strains and clinical
13
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isolates of P. aeruginosa (Chapter 2) and S. aureus (Chapter 3) in vitro,
using laser-based photoacoustic spectroscopy, as wel as from P. aeruginosa
and A. fumigatus mono- and co-cultures using GC-MS (Chapter 4). Fur-
thermore, VOCs in exhaled breath of S. aureus infected and non-infected
CF patients were studied using both techniques (Chapter 3 and 5). The
main findings of this thesis are summarized, and future perspectives are
discussed (Chapter 6).
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Real-time monitoring of hydrogen cyanide
(HCN) and ammonia (NH3) emitted by Pseu-
domonas aeruginosa
2
We present the real-time monitoring of hydrogen cyanide (HCN) production from
Pseudomonas aeruginosa (P. aeruginosa) strains in vitro, using laser-based pho-
toacoustic spectroscopy. Simultaneously, the production of ammonia (NH3) was
measured, and the influence of different factors (e.g. the medium, temperature,
and antibiotics treatment) was assessed. Both reference strains and clinical isolates
of patients with CF were studied, and compared to other pathogens commonly
present in lungs/airways of CF patients. Hydrogen cyanide production starts to
rise as soon as P. aeruginosa bacteria reach the stationary phase (9.0 - 9.5 x 109
colony forming units, CFUs), up to concentrations of 14.5 microliters per hour
(µ/h). Different strains of P. aeruginosa produced HCN to varying degrees, and
addition of tobramycin strongly reduced HCN production within 2 hours from
application. Burkholderia cepacia also produced HCN (up to 0.35 µL/h in 9.0 x
109 CFU) while other pathogens (Aspergillus fumigatus, Stenotrophomonas mal-
tophilia, Mycobacterium abscessus) did not produce detectable levels. Our study
reveals for the first time a broad overview of the dynamics of the HCN production
in vitro.
Published in Journal of Breath Research 2015, 9: 027102
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2.1 Introduction
Cystic fibrosis (CF) is a multisystem disease leading to chronic respiratory in-
fections, that results in progressive loss of lung function and diminished life ex-
pectancy. Pseudomonas aeruginosa (P. aeruginosa) is one of the most common
pathogens causing these infections. The presence of this opportunistic Gram-
negative bacterium is associated with a high morbidity and mortality rate [1, 2].
Initially, P. aeruginosa grows as a non-mucoid strain which often can be eradi-
cated with aggressive antibiotic treatment [3]. However, over time the phenotype
changes to mucoid, complicating eradication. To detect and monitor P. aerugi-
nosa colonization or infection, it is recommended to screen patients frequently for
P. aeruginosa colonization, and once isolated, start with aggressive eradication
therapy. The current golden standard for detection of P. aeruginosa is a sputum
culture. However, young CF patients are not able to expectorate adequate sam-
ples. Alternatives have therefore been sought and include invasive (bronchoscopy),
non-specific (chest X-ray) [3], or unreliable (cough swabs) methods [4]. For this
reason, there is an urgent need for a quick, patient-friendly, reliable, safe, and sen-
sitive method to diagnose P. aeruginosa infection in an early stage. The ability
of P. aeruginosa to synthesize hydrogen cyanide (HCN) can be the base of this
diagnosis.
Cyanogenesis or HCN synthesis occurs only in a few bacterial species, including
P. aeruginosa. Cyanide is a secondary metabolite that can inhibit many cellular
processes. It is well known that HCN inhibits aerobic respiration [5]. However, the
exact physiological role of cyanide production in bacteria is still not completely un-
derstood. Giving the toxicity of cyanide, P. aeruginosa may also have advantages
in excluding other pathogens in the lungs of CF patients [5] .
Hydrogen cyanide is detectable in the headspace of P. aeruginosa cultures in
vitro [6-8], and is present in the sputum of P. aeruginosa infected CF patients
[1, 4]. Different studies have been published on the detection of HCN in exhaled
breath of P. aeruginosa infected patients compared to non-infected patients, using
selected ion flow tube mass spectrometry (SIFT-MS) [9-11]. Based on these results,
HCN has been established as a true marker for P. aeruginosa infection [6-8, 12-
14]. However, there is a lack of a complete overview of the HCN production, since
other techniques measured HCN production in vitro at a maximum of four discrete
time points after inoculation, starting from 24 h up to 92 h [7, 12]. Therefore,
further investigation of the dynamics of HCN release is needed to better understand
physiological mechanisms.
The aim of this study was to assess the dynamics of the HCN production
from P. aeruginosa strains in vitro, in real-time, using laser-based photoacoustic
spectroscopy. Both commercially available reference strains and clinical isolates
of patients with CF were studied and several other species, e.g. Burkholderia
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cepacia (B. cepacia), Stenotrophomonas maltophilia (S. maltophilia), Aspergillus
fumigatus (A. fumigatus) and Mycobacterium abscessus (M. abscessus), were used
as controls and their ability to produce HCN has been tested. To gain better insight
into production mechanisms, the influence of different factors (e.g. temperature,
media, and antibiotic treatment) were studied. In parallel, we also monitored
ammonia (NH3) from P. aeruginosa, since this compound has been found to result
from the metabolism of nitrile compounds and their derivatives [15].
2.2 Materials and Methods
2.2.1 Bacterial strains
Five clinical isolates and three reference strains of P. aeruginosa (ATCC 10145,
ATCC 27853 and ATCC 9027) were selected for this study. Clinical isolates were
selected to reflect the range of P. aeruginosa phenotypes commonly observed in
CF patients (table 2.1). Clinical isolates were primarily isolated on Columbia
sheep blood agar and MacConkey agar during routine clinical evaluations.
The five P. aeruginosa clinical isolates, and the three reference strains had
been stored in brain heart infusion (BHI) broth at 80 ◦C and were inoculated into
50 mL BHI broth (Mediaproduct BV, The Netherlands) in an initial concentration
of approximately 5 x 10 6 colony forming units (CFU)/mL.
Burkholderia cepacia (ATCC 24516), S. maltophilia (ATCC 49489), A. fumi-
gatus (AZN 8196; isolate obtained from a patient with proven invasive aspergillo-
sis) and M. abscessus (CIP 104536) were cultured under the same experimental
conditions.
2.2.2 Growth curves and susceptibility testing
Growth curves were obtained following standard procedures. Briefly, BHI was
inoculated with 5 x 106 CFU/mL P. aeruginosa as described above. Samples
for CFU counting of the reference strains were taken at 30 minutes, every hour
from 1 to 8 hours, every 2 hours from 8 to 16 hours, every 4 hours from 16 to 24
hours, and every 8 hours from 24 till 48 hours. The clinical isolates were counted
at 2 hours, every 4 hours from 8 to 16 hours, at 22 hours, every 4 hours from
22 to 34, and 42 hours after inoculation. Serial ten-fold dilutions were made in
saline (0.9 % NaCl); 10 µL were plated in triplicate on Mueller Hinton agar plates
(Oxoid). After approximately 12 hours, the colonies on the plates were counted
manually and the CFU/mL was calculated.
The minimal inhibitory concentrations (MICs) for tobramycin were deter-
mined using a broth microdilution method with a concentration range of 0.5 to
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Table 2.1: Characteristics of P. aeruginosa reference strains and clinical isolates
Name
Strain
identifier
Phenotype
Characteristics
CF patient
Simultaneously
present
bacteria
Reference
(type strain)
ATCC 10145 Non-mucoid
Reference ATCC 27853 Non-mucoid
Reference ATCC 9027 Mucoid
Clinical
isolate 1
B13020052-1 Mucoid M, 35yr
Other
P. aeruginosa
Clinical
isolate 2
B11097119-4
Dry, rough
colonies
F, 20yr
Other
P. aeruginosa
Clinical
isolate 3
B10019044-5 Mucoid M, 12yr
Other
P. aeruginosa
Clinical
isolate 4
B11094822-3
Fastidious,
slow
F, 24yr
Other
P. aeruginosa
Clinical
isolate 5
B11095407-3
Fastidious,
slow
M, 52yr
Other
P. aeruginosa.
S. aureus
8 mg/L (Sensititre, Thermofisher, USA). Tests were performed according to the
manufacturers instruction. Briefly, a 96 well microtitreplate plate with freeze-
dried tobramycin was inoculated with 100 µL cation-adjusted Mueller Hinton
(caMH) broth with N -Tris-(Hydroxymethyl)Methyl-2-aminoethanesulfonic acid
(TES) (Sensititre, Thermofisher, USA) containing 5 x 105 CFU/mL. Plates were
visually checked after 16-24 hours incubation at 37 ◦C. The lowest concentration
without visible growth was considered to be the MIC.
2.2.3 Headspace analysis
For the headspace analysis, the bacteria were cultured in an environmental cham-
ber (Sanyo Versatile Environmental Test Chamber, Osaka, Japan) at 37 ◦C, while
constantly shaking on an orbital shaker (Sanyo orbital shaker, Osaka, Japan) at
100 revolutions per minute (rpm) in a 250 mL Erlenmeyer flask. Each flask was
adapted for gas sampling with a glass stopper, containing two Teflon open-close
valves acting as the gas inlet and outlet. To prevent bacterial contamination, bac-
terial filters (FP 30/0.2 Ca/S, Whatman GmbH, Germany) were placed on the
inlet and outlet of the flasks. The headspaces of bacterial samples were constantly
flushed with 3.5 L/h compressed air, of which 3 L/h were sent to the photoacoustic
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cell. Sterile BHI and caMH broth media, kept under the same environmental con-
ditions as the bacterial cultures, were used as control experiments. All headspace
measurements were performed at least in triplicate.
2.2.4 Experimental conditions
Four P. aeruginosa strains (2 reference strains and 2 clinical CF isolates) were
randomly selected to be cultured under different environmental conditions. The
strains were cultured in two media (BHI broth and caMH broth) using the same
methodology as described above. Additionally, the effect of temperature was tested
by culturing the bacteria in BHI at 40 ◦C.
To test the effect of tobramycin on HCN production by P. aeruginosa, 1 x MIC
of tobramycin (Duchefa Farma, Haarlem, the Netherlands) was applied to a culture
of reference strain ATCC 10145, 20 hours after inoculation. The CFU counts
before administration of tobramycin, and 1, 2, 4 and 8 hours after administration of
tobramycin, were performed according to the counting-procedure described above.
2.2.5 Laser-based photoacoustic spectroscopy
The concentration of HCN in the headspace of P. aeruginosa bacteria was analyzed
using laser-based photoacoustic spectroscopy. The setup was described previously
by Arslanov et al. [16] and only a short description will be given. The setup
consisted of a continuous wave Optical Parametric Oscillator (OPO) delivering
up to 500 mW laser power in the mid-infrared spectral region (from 2.8 µm to
3.7 µm). The wavelength of the OPO was scanning from 3286.5 to 3288.0 cm−1
(3041.4 nm - 3042.8 nm) for the experiments described in this article. Within this
spectral range, both HCN and NH3 were measured simultaneously. The walls of
the cell were coated with Teflon® PFA to prevent loss of HCN trough adsorption
of the gas by the cell wall material. The system allows a detection limit of 0.4 ppbv
of HCN and 1 ppmv of NH3 in 10 seconds. The calibration was performed under
similar conditions as in the in vitro measurements, using a standard mixture of 5
ppm HCN in nitrogen (5 ppmv, +/- 5%, 10 liter cylinder, Linde, The Netherlands).
A Teflon valve system was used to connect up to 6 samples to the photoacoustic
system. This system allows to automatically and periodically switch between
the samples. For the experiments in this study, a total measuring time of 15
minutes per sample was used. To discard the transition phase from the previous
measurement, averages of the last 3 minutes are plotted. The pattern of HCN
and NH3 is expressed as the production rate in microliters per hour (µL/h) by
multiplying the concentration (nano liter per liter) with the flushing flow rate
(liters per hour). By plotting the production rate against time and integrating
the area under the curve, we calculated the total production (nL). This is used
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to compare the HCN and NH3 production of the strains (e.g. under different
environmental conditions) over a period of 120 hours.
2.2.6 Statistical analysis
The experimental data derived from the growth curves were analyzed using Graph-
pad prism 5.03 (Graphpad Inc., San Diego, CA). Log CFU count values were
plotted against time for each strain, and by use of nonlinear regression model one
phase exponential association a curve fit was performed.
Using a paired sample t-test, the HCN production differences under different
environmental conditions were tested for significance.
2.3 Results
2.3.1 Growth curves and susceptibility
The growth curves for all P. aeruginosa strains are shown in figure 2.1. Growth
curves for each strain differ. In general, reference strains grow faster and reach
stationary phase earlier (12 - 16 hours) than clinical isolates (20 - 30 hours).
The MIC for reference strain ATCC 10145 was ≤ 0.5 mg/L. All MICs were
higher for clinical isolates than for the reference strains, ranging from 2-8 mg/L
(data not shown).
2.3.2 HCN and NH3 production by P. aeruginosa
The HCN production by all P. aeruginosa strains is shown in figure 2.2(a, c). The
dynamics of production varied across the different strains. The highest levels of
HCN were produced by reference strain ATCC 10145. The maximum production
rate of this strain ranges from 9.9 to 14.5 µL/h. The lowest levels were produced
by clinical isolate 3, with maximum levels of 466 nL/h. The HCN production was
found not to be correlated with the amount of bacteria present (CFU). Overall, the
reference strains start to produce HCN earlier (9 - 17 hours) than clinical isolates
(18 - 30 hours). Among the reference strains, non-mucoid strains (ATCC 10145 and
28753) produced higher levels of HCN compared the mucoid strain (ATCC 9027).
However, this phenomenon was not seen among the clinical isolates. Production
of HCN from BHI broth media was below detection limit.
Simultaneously with the HCN measurements, NH3 was also measured in real-
time from the same bacterial samples. Ammonia production rates of BHI broth
media (control) were stable around 100 µL/h. Figure 2.2 shows the NH3 pro-
duction by three P. aeruginosa reference strains (b) and four clinical isolates (d).
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Figure 2.1: Growth curves of P. aeruginosa reference strains (a) and five clinical isolates
(b). The strains are indicated by different symbols. The numbers of the clinical isolates
correspond to the numbers in table 2.1. CFU: colony forming units.
The release of NH3 by P. aeruginosa started simultaneously with HCN produc-
tion. It reached maximum levels between 1000 and 3000 µL/h in different strains,
far higher quantities as compared to HCN production. All strains still produce
NH3 after HCN production decreased to the detection limit of the system.
2.3.3 Different environmental conditions
To investigate the effect of the environment on HCN production by P. aeruginosa,
two reference strains and two clinical isolates were cultured in two media (BHI
and caMH broth) and in BHI broth at two temperatures (37 and 40 ◦C) (figure
2.3). Except for clinical isolate 3, the production of HCN at 37 ◦C is significantly
higher than at 40 ◦C (figure 2.3a). The total production of HCN is significantly
higher in caMH cultures than in BHI ones for the two reference strains and clinical
isolate 5, but significantly lower for clinical isolate 3 (figure 2.3b).
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Figure 2.2: Representative production patterns of HCN (a) and NH3 (b) by P. aerugi-
nosa reference strains, and of HCN (c) and NH3 (d) by clinical isolates. The strains are
indicated by different symbols. The numbers of the clinical isolates correspond to the
numbers in table 2.1. Points are displayed every 3 hours for easy viewing, while data was
collected every 1.5 hours.
Figure 2.3: HCN production of P. aeruginosa strains ATCC 10145, ATCC 9027 and
clinical isolate 3 and 5, cultured in BHI at 37 ◦C or 40 ◦C (a) and in BHI or caMH (b).
The numbers of the clinical isolates correspond to the numbers in table 2.1. BHI: brain
heart infusion broth. caMH: cation-adjusted Mueller-Hinton broth. Data represent mean
+/- SD (n=3), * p < 0.01, **p < 0.05.
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Figure 2.4: HCN production (a) and colony forming unit (CFU) counts (b) of P. aerug-
inosa reference strain ATCC 10145 with (•) and without () administration of 1 MIC
tobramycin, 20 hours after inoculation. To test reproducibility, the experiments were
performed in duplicate.
2.3.4 The effect of Tobramycin on HCN production
As a proof of concept experiment, we studied the effect of antibiotic treatment on
HCN production of P. aeruginosa. A concentration of 1 x MIC of tobramycin was
added to reference strain ATCC 10145, 20 hours after inoculation and the HCN
production was then monitored for 8 hours after antibiotic administration (figure
2.4a). The HCN released by antibiotic treated samples started to decline within
2 hours after tobramycin application, as compared to samples not treated. At the
same time, the CFU decreased 2 hours after administration of tobramycin as well
(figure 2.4b).
2.3.5 HCN production by other CF-related pathogens
Among the other CF-related pathogens tested for HCN production, B. cepacia
was the only species producing HCN. It reached maximum levels of 0.35 µL/h, 25
hours after inoculation (figure 2.5). Stenotrophomonas maltophilia, A. fumigatus
and M. abscessus did not produce detectable levels of HCN (data not shown).
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Figure 2.5: Typical representation of HCN production pattern by B. cepacia.
2.4 Discussion
This study is the first to investigate the HCN production dynamics of different
P. aeruginosa strains in vitro, in real-time, using laser-based photoacoustic spec-
troscopy. We determined the growth and HCN production pattern of both refer-
ence strains and clinical isolates, and provided insight into the influence of different
environmental factors (temperature, media, and antibiotic treatment) on the HCN
production. Furthermore, various other pathogens in lungs of CF patients were
tested for HCN production.
Several in vivo studies reported no HCN in exhaled breath of P. aeruginosa
infected patients [9-11]. The results of this study may offer an explanation for this.
We confirmed the findings by Gilchrist et al. [7] that all P. aeruginosa strains
produce HCN. However, there are clear differences in absolute quantities. For all
8 strains, we calculated the total volume of HCN produced. This volume ranges
from 7.2 µL - 444.2 µL over 120 hours. Furthermore, the production patterns
among the different strains vary. Overall, reference strains started to produce
HCN earlier (9 - 17 hours) than clinical isolates (18 - 30 hours). Also the length
of production in time, is different in all the strains. While some strains are able to
produce HCN for approximately 4 days, others stop producing already after 1 day.
By comparing the frequent CFU counts with the quantity of HCN produced, it
can be concluded that the quantity of HCN produced is independent of bacterial
mass. Furthermore, the HCN production capacity per CFU is found to be different
among the 8 strains tested.
The production of HCN by P. aeruginosa is found to be maximal under mi-
croaerobic (O2 < 5%) conditions [10, 17, 18], increased bacterial cell density [10]
and at temperatures between 34 ◦C and 37 ◦C [10, 11]. Similar levels of HCN are
produced when P. aeruginosa is cultured under planktonic conditions compared
to biofilm conditions [12]. Our study illustrates that the environmental condi-
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tions are important factors contributing to a large variability in HCN production.
When P. aeruginosa was cultured in caMH broth, absolute HCN production was
significantly higher in 3 of the four tested strains. Only clinical isolate 3 showed
significantly lower values. Furthermore, the production pattern was different, with
peaks appearing at other time points (data not shown). Under higher environmen-
tal temperatures (40 ◦C versus 37 ◦C) absolute HCN production was significantly
lower in 3 of the 4 strains tested. This is an important aspect to be considered in
clinical settings (e.g. patients with fever).
Pseudomonas aeruginosa produces cyanide by oxidative decarboxylation of
its immediate precursor, glycine [19, 20]. Under physiological conditions at pH
7, cyanide is mostly present as hydrogen cyanide (HCN), according to its pKa
of 9.3. HCN is a toxic compound that inhibits aerobic respiration. Castric et
al. [21] described in 1979 that HCN production is maximal during the transition
from the exponential growth phase to the stationary growth phase. By comparing
the HCN production with bacterial growth, we demonstrate that HCN production
starts as soon as the bacteria reach stationary phase (during the transition from the
exponential growth phase to the stationary growth phase). However, maximum
levels are not yet reached in this stage. For example, clinical isolate 1 and 5
produced maximal levels in late stationary phase. Since the reference strains
reach stationary phase earlier (12 - 16 hours) than clinical isolates (20 - 30 hours),
HCN production also started earlier in these strains. After reaching the maximum,
HCN production decreases. This might be caused by depletion of nutrients. In
a previous study, we confirmed this hypothesis by adding medium after HCN
reached levels corresponding to the detection limit of the system, which resulted
in a burst of the HCN production [16]. Furthermore, it has been suggested that
strains with a mucoid phenotype produce higher levels of cyanide compared to
non-mucoid strains [22, 23], while the opposite with non-mucoid cultures with
higher HCN concentrations was also reported [7]. Our data shows that the effect
of phenotype (mucoid versus non-mucoid) varies between strains (reference strains
versus clinical strains).
In parallel with the HCN measurements, we also monitored on-line the NH3
production. It has been reported that P. aeruginosa can prevent HCN levels from
becoming toxic by converting it into ammonia (NH3), using specific enzymes [24].
Not much information is available about NH3 production by P. aeruginosa in vitro.
Very recently, high concentrations of ammonia have been detected in the headspace
of A. fumigatus [13], while the respiratory pathogens Staphylococcus aureus, Strep-
tococcus pneumoniae and Haemophilus influenzae did not show such high levels
[25]. To the best of our knowledge, this is the first study that shows the dynamics
of NH3 production by P. aeruginosa in vitro, in real-time. Our results show that
P. aeruginosa has the capability to produce HCN and NH3, with the latter being
released in far greater quantities. It is known that P. aeruginosa makes NH3 as
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a result of nitrile metabolism [15], and that it is equipped with mechanisms to
detoxify HCN [26, 27]. Furthermore, it is reported that Pseudomonas fluorescence
can enzymatically convert HCN into NH3 [24]. Whether P. aeruginosa possesses
similar ability to directly convert HCN into NH3 needs further investigation.
To investigate whether HCN can be potentially used to monitor antibiotic
treatment, we studied the effect of tobramycin on HCN production. Tobramycin is
a commonly used antibiotic against P. aeruginosa infection in CF-patients because
it shows high activity against this pathogen and the frequency of resistance is
lower than other commonly used therapies [28]. Administration of tobramycin to
reference strain ATCC 10145, leads to a decrease in HCN production within 2 hours
following the treatment, and simultaneously a decrease in CFUs. We believe that
this is the first study that investigated the effect of antibiotic treatment on HCN
production in P. aeruginosa. The results indicate that HCN detection can provide
a useful tool for monitoring the effect of antibiotic treatment on P. aeruginosa
infection in patients.
Initially, it was thought that P. aeruginosa was the only organism in the CF
lung able to produce HCN. However, in 2008, nonvolatile cyanide ions were de-
tected in cultures of B. cepacia under biofilm and colonial growth conditions [29].
A recent study investigating whether HCN is an in vitro or in vivo marker for
B. cepacia complex (BCC), did not find elevated HCN levels in the headspace of
the cultures neither in exhaled breath of CF patients with chronic BCC infection
[30]. In contrast to this study, we found elevated HCN levels in the headspace of
B. cepacia reference strain ATCC 24516. Burkholderia cepacia, originally named
Pseudomonas cepacia, and P. aeruginosa are closely related organisms. There-
fore, cyanide and/or HCN production may be a shared feature of P. aeruginosa
and B. cepacia. More strains of B. cepacia need to be studied to clarify these
contradictions. Except for B. cepacia, we could not detect any HCN production
in several other CF pathogens which consistent with the literature renders HCN
a specific marker for P. aeruginosa, and possibly for B. cepacia.
In vitro measurements constitute a setting very different from the in vivo
situation, where the lung environment, polymicrobial infections, and drug therapy
create a different environment for P. aeruginosa. However, although exploratory,
this study may offer some insight into the HCN production dynamics in the lung
of CF patients. By investigating on-line and real-time the production of volatiles
in vitro, the disadvantage of poor time resolution, in which important production
features may be missed, are overcome. This might explain why very low HCN
levels were detected at discrete time points in earlier reports [6, 7]. Still, further
in vivo studies are needed to assess whether HCN production constitutes a risk
factor for a poor prognosis.
In conclusion, the measurements performed in this study provide basic infor-
mation about real-time HCN production patterns by P. aeruginosa in vitro. All
34
2Acknowledgements
reference strains and clinical isolates produced HCN, and production starts as
soon as the bacteria reach stationary phase with clear differences in quantities and
production patterns. Furthermore, simultaneously with HCN, large quantities of
NH3 are also produced, presumably to prevent HCN toxicity.
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Hydrogen cyanide (HCN) emission in the lung
by Staphylococcus aureus
3
Hydrogen cyanide (HCN) is proposed as specific biomarker for Pseudomonas aerug-
inosa detection in cystic fibrosis (CF) patients. However, proof that HCN is not
produced by Staphylococcus aureus (S. aureus) is limited. We therefore investi-
gated the HCN production by S. aureus in vitro, and HCN levels in the exhaled
breath of S. aureus infected CF patients, using non-infected CF patients, as well as
healthy persons as controls. Applying laser-based photoacoustic spectroscopy, the
dynamics of HCN production in five clinical isolates from sputum obtained from
CF patients was monitored. Furthermore, we investigated whether the S. aureus
strains cultured from patients in whom HCN was detected in exhaled breath, were
capable of producing HCN. All strains produced HCN in vitro. Levels of HCN in
exhaled breath of S. aureus infected CF patients were significantly higher com-
pared to the controls (median (IQR), 38.0 (25.9 to 71.3) vs 24.2 (11.3 to 32.1)
pmol/mL CO2, p = 0.01). Furthermore, HCN production levels of the S. au-
reus strains isolated from sputum and breath HCN levels are strongly correlated
(Spearman r = 0.97). Our results demonstrate that HCN is produced by S. aureus
in vitro and in vivo, and is not an exclusive biomarker for P. aeruginosa infection.
Published in European Respiratory Journal 2016, ERJ-02093-2015
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3.1 Introduction
Early detection of Pseudomonas aeruginosa in cystic fibrosis (CF) patients is cru-
cial, since eradication in a later stage is extremely difficult [1]. Until now, it
has been assumed that hydrogen cyanide (HCN) can be considered as a specific
biomarker for P. aeruginosa in exhaled breath [2-5]. Only Burkholderia cepacia
is also known to produce HCN in vitro [6, 7], but HCN is not a biomarker for
B. cepacia complex infection in vivo [8]. To our knowledge, actual proof that
HCN is not produced by other pathogens is lacking. Investigations into the emis-
sion of HCN by Staphylococcus aureus, a predominant CF pathogen throughout
childhood, have been very limited. In a single report, five strains have been shown
to produce low values in vitro [9], and in vivo studies have not been reported.
We therefore measured the real-time HCN production by clinical S. aureus
isolates in vitro, and HCN levels in the exhaled breath of S. aureus infected CF
patients, in comparison with non-infected CF patients, as well as healthy persons
as controls. Furthermore, we investigated whether the S. aureus strains cultured
from patients in whom HCN was detected in breath, were capable of producing
HCN.
3.2 Materials and Methods
Five clinical isolates of S. aureus from sputum were inoculated into 50 mL brain
heart infusion (BHI) broth in an initial concentration of 5 x 106 colony forming
units (CFU)/mL. The setup used for analyzing the bacterial headspace (n=3 per
isolate) and determination of growth curves has been previously described [6].
Cystic fibrosis patients (≥ 6 years old) were recruited from the outpatient clinic
of Radboud University Medical Center, Nijmegen, and Erasmus Medical Center,
Rotterdam, the Netherlands. This study was approved by the local medical ethics
committee (CMO Nijmegen/Arnhem) which waived written informed consent.
Oral consent was obtained from both participants aged 12 years and older, and
from parents of children aged 6-18 years.
We included non-smoking, infected and non-infected CF patients and healthy
controls. Infection was defined as culturing S. aureus, P. aeruginosa or B. cepacia
in sputum on the day of breath sampling or in >50% of sputum samples (minimum
of 4 samples) over the previous 12 months. Free of infection was defined as no
S. aureus, P. aeruginosa or B. cepacia in sputum samples (minimum of 4 samples)
over the previous 12 months. Sputum samples were obtained as a part of routine
clinical care. Before sampling, all participants rinsed their mouth with water.
Each subject provided two single mouth-exhaled breath samples that were col-
lected in separate 3L Tedlar® bags (ProCare B.V., Groningen, The Netherlands)
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at a constant flow rate of 300 mL s−1, using a breath sampler (Loccioni, Angeli di
Rosora, Italy) [10]. Briefly, the participants exhaled through a bacterial filter (Air
Safety Limited, Lancashire, UK) and a non-rebreathable T-piece (Vacumed, Ven-
tura, USA) which were connected to a CO2 sensor and a calibrated buffer pipe.
From the total exhalation, the dead space air (150 mL) was discarded and the
remaining part collected in the sampling bag. The breath samples were collected
separated by 90 seconds and stored for a maximum of 8 hours prior to analysis.
Quantification of HCN in breath was performed using laser-based photoacoustic
spectroscopy as described earlier [8, 13]. Exhaled HCN levels were normalized to
respiratory CO2 concentration and mean values (n=2) were considered for analy-
sis.
To validate whether the particular S. aureus strains from randomly selected
S. aureus infected patients in whom HCN was detected in breath were capable
of producing HCN, we measured the HCN production from 5 separately cultured
S. aureus strains. The strains were isolated from sputum that was collected on
the day of breath sampling. The total production of HCN in vitro over 30 hours
was compared with the level in breath of the corresponding patients.
3.3 Results
The growth of all S. aureus strains was monitored for 48 hours from the time
of inoculation (figure 3.1). All strains showed comparable concentrations in the
stationary phase (108 - 109 CFU/mL). Clinical isolate 1, 2 and 3 reached the
stationary phase at 16 hours after inoculation, while number 4 and 5 grew slower
and reached stationary phase after approximately 20 hours.
Figure 3.1: Growth curves of S. aureus clinical isolates. The strains are indicated by
different symbols. The numbers of the clinical isolates correspond to the numbers in
figure 3.2a. CFU: colony forming units.
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All S. aureus clinical isolates in vitro produced HCN, although the production
level was different across the strains (figure 3.2a). Production started at approx-
imately 3 hours, reached a maximum at 6-7 hours, and decreased towards the
detection limit, 24-30 hours after inoculation. The absolute production ranged
from (mean +/- SD) 45.8 +/- 37.4 (isolate 3) to 994.2 +/- 807.0 nmol (isolate 2)
over 30 hours.
We included 17 CF patients infected with S. aureus (10 with S. aureus in
sputum on the day of breath sampling and 7 with S. aureus in >50% of sputum
samples, median (IQR) age; 15 (11 - 31.5) years), and a combined group of 8 CF
patients free from S. aureus infection and 12 healthy controls (median (IQR) age;
24 (21 - 28) years). Exhaled HCN levels of S. aureus infected CF patients, were
significantly higher compared to the combined group of non-infected CF patients
and healthy controls (median (IQR), 38.0 (25.9 - 71.3) vs 21.9 (6.8 - 32.8) pmol/mL
CO2, p = 0.01). No statistical difference was found for HCN levels in breath of
non-infected CF patients compared to healthy controls (median (IQR), 21.7 (7.0
- 48.6) vs 19.6 (3.4 - 30.7) pmol/mL CO2, p = 0.85).
The HCN production levels of the S. aureus strains isolated from sputum on
the day of breath sampling are higher compared to breath HCN levels, and are
strongly correlated (Spearman r = 0.97) (figure 3.2b).
Figure 3.2: Hydrogen cyanide production of 10 S. aureus strains. a: In vitro production
rates of 5 clinical S. aureus strains from sputum of CF patients. b: Production by 5
S. aureus strains isolated from sputum of CF patients (others than in fig. 1a) that was
collected on the day of breath sampling in triplicate (4), versus the concentration of
HCN in exhaled breath in duplicate (•) (Spearman r = 0.97).
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3.4 Discussion
This study demonstrates that HCN is produced by S. aureus in vitro and is present
in exhaled breath of S. aureus infected CF patients. Gilchrist and co-workers cul-
tured five strains of S. aureus on blood agar and reported HCN concentrations of
1 to 6 parts per billion by volume at 24, 48, 72 and 96 hours [9], which are lower
compared to those measured in our study. Variations in strain, culturing method
(planktonic vs biofilm conditions), medium (BHI vs blood agar) or sampling time
points may account for these differences. By comparing the HCN production dy-
namics with bacterial growth curves it can be concluded that S. aureus starts to
produce HCN in the exponential growth phase and varies between strains. Hydro-
gen cyanide is a highly toxic compound, well-known to inhibit cellular respiration
[11]. We speculate that the differences in absolute production may contribute to
differences in virulence between S. aureus strains, since HCN is associated with
lung damage, impaired lung function [12] and reduction of the host response ef-
fectiveness in CF [13]. Therefore, patients with elevated HCN levels might benefit
from aggressive antibiotic treatment in early CF lung disease. The HCN levels
in S. aureus infected patients are significantly higher compared to a combined
group of non-infected patients and healthy controls. The correlated HCN levels in
vitro and in breath indicate that the breath HCN levels originate from S. aureus
infection in the lung.
Our results show that HCN in exhaled breath is not an exclusive biomarker for
P. aeruginosa infection, which is a significant drawback in the attempt to develop
a specific diagnostic tool for early detection of P. aeruginosa in patients with CF.
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Identification of Pseudomonas aeruginosa and
Aspergillus fumigatus mono- and co-cultures
based on volatile biomarker combinations
4
Volatile Organic Compound (VOC) analysis in exhaled breath is proposed as a
non-invasive method to detect respiratory infections in cystic fibrosis patients.
Since polymicrobial infections are common, we assessed whether we could distin-
guish Pseudomonas aeruginosa and Aspergillus fumigatus mono- and co-cultures
using the VOC emissions. We took headspace samples of P. aeruginosa, A. fu-
migatus and co-cultures at 16, 24 and 48 hours after inoculation, in which VOCs
were identified by thermal desorption combined with gas chromatography - mass
spectrometry. Using multivariate analysis by Partial Least Squares Discriminant
Analysis (PLS - DA) we found distinct VOC biomarker combinations for mono-
and co-cultures at each sampling time point, showing that there is an interaction
between the two pathogens, with P. aeruginosa dominating the co-culture at 48h.
Furthermore, time-independent VOC biomarker combinations were also obtained
to predict correct identification of P. aeruginosa and A. fumigatus in mono-culture
and in co-culture. This study shows that the VOC combinations in P. aeruginosa
and A. fumigatus co-microbial environment are different from those released by
these pathogens in mono-culture. Using advanced data analysis techniques such
as PLS-DA, time-independent pathogen specific biomarker combinations can be
generated that may help to detect mixed respiratory infections in exhaled breath
of cystic fibrosis patients.
Published in Journal of Breath Research 2016, 10: 016002
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4.1 Introduction
Respiratory infections are a major problem for cystic fibrosis (CF) patients. The
abnormally viscous mucus within their lungs provides an optimal environment for
pathogens to grow, resulting in colonization and infection. Pseudomonas aerug-
inosa is an environmental bacterium that colonizes CF patients very often. It
represents an important public health problem, since its presence is associated
with high morbidity and mortality [1, 2]. Fungal colonization also plays an im-
portant role, and is increasingly recognized in the CF lung [3, 4]. Aspergillus
fumigatus, found in abundance throughout the environment, is by far the most
reported filamentous fungus in the respiratory tract of CF patients [3, 5]. Since
P. aeruginosa and A. fumigatus are common pathogens, co-infection with these
two pathogens is seen relatively often. Recent studies reported the incidence of
P. aeruginosa in 54 - 64 % of the sputum samples of CF patients colonized with
A. fumigatus [6, 7]. Furthermore, these co-infections are correlated with a signif-
icant reduction of lung function in patients with CF, and a higher exacerbation
and hospitalization rate compared to patients only infected with A. fumigatus [7].
Detection of respiratory infections in CF patients is currently based on spu-
tum cultures. Unfortunately, adequate sputum samples may be difficult to obtain,
especially in young or severely ill patients. Current alternatives are either invasive
or lack the sensitivity necessary for clinical diagnosis. Therefore, a suitably sensi-
tive, non-invasive alternative should be sought to detect respiratory infections in
an earlier stage [8].
Volatile Organic Compounds (VOCs) in exhaled breath have been proposed
as a non-invasive diagnostic tool to detect respiratory infections. As ultimate goal,
by identifying specific biomarkers for the presence of a pathogen in vitro, it might
be possible to detect infections in exhaled breath in vivo. However, it is unknown
whether VOCs released by P. aeruginosa and A. fumigatus are constant or change
in the presence of other pathogens due to e.g. interspecies competition.
The aim of this study was to assess whether we could distinguish P. aerugi-
nosa and A. fumigatus mono-and co-cultures based on their VOCs emissions in
vitro. Therefore, the headspace of mono-cultures of P. aeruginosa, and of A. fu-
migatus, and co-cultures was analyzed at three time points (16, 24 and 48 hours
after inoculation) by using the widely accepted standard for VOC detection, Gas
Chromatography - Mass Spectrometry (GC-MS). A dedicated data analysis strat-
egy based on multivariate analysis by Partial Least Squares Discriminant Analysis
(PLS-DA) was developed to determine specific time-independent VOC biomarkers
for the presence of P. aeruginosa, A. fumigatus or both.
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4.2 Materials and Methods
4.2.1 Cultures
Pseudomonas aeruginosa (strain ATCC 27853) and a clinical isolate ofA. fumiga-
tus (AZN 8196 clinical isolate), were selected for this study.
Pseudomonas aeruginosa was inoculated into 50 mL Brain Heart Infusion
(BHI) broth (Mediaproducts BV, The Netherlands) in an initial concentration of
approximately 5 x 106 colony forming units (CFU)/mL.
Aspergillus fumigatus was stored in 10% glycerol broth at -80 ◦C, and revived
by subculturing on Sabouraud dextrose agar (SAD) supplemented with 0.02%
chloramphenicol, for 2 x 7 days at 37 ◦C. Using a swab, the conidia were har-
vested and suspended into 5 mL of BHI broth plus 0.1% Tween 80 (Boom B.V.,
Meppel, The Netherlands) until an average concentration of 2.6 x 106 CFU/mL
was reached, as assessed by measuring the transmission using a spectrophotometer
at 530 nm [9]. This suspension was further diluted (10x) into 50 mL BHI broth
to a final concentration of 2.6 x 105 CFU/mL.
Co-cultures (cultures with both A. fumigatus and P. aeruginosa) were ob-
tained by preparing a culture of A. fumigatus (2.6 x 105 CFU/mL) as described
above. Since P. aeruginosa was expected to overgrow A. fumigatus if both pathogens
are inoculated simultaneously, P. aeruginosa (5 x 106 CFU/mL) was manually
added fifteen hours after the inoculation of A. fumigatus.
4.2.2 Growth curves
The growth of A. fumigatus in mono- and co-culture was assessed by measuring
galactomannan levels in the growth medium [10]. Samples were taken at 1 hour,
6, 12, 20, 24 and 48 hours after inoculation. Determination of galactomannan
concentrations in the medium was performed by the Platelia Aspergillus Enzyme
Immuno Assay (EIA) (Platelia Aspergillus; Sanofi Diagnostics, Marnes-La Co-
quette, France) according to the manufacturers instructions. Values of EIA were
expressed as galactomannan index (GI) plotted over time.
The growth of P. aeruginosa in mono-culture was monitored by counting the
colony forming units (CFU) according to standard procedures. In brief, samples
for CFU counting were taken at 30 minutes after inoculation of the bacteria, then
subsequently every hour from 1 to 8 hours, every 2 hours from 8 to 16 hours,
every 8 hours from 16 to 32 hours and finally at 48 hours. Tenfold serial dilutions
of these samples were made in saline (0.9% NaCl), 10 L was subsequently plated
in triplicate on Mueller Hinton agar plates (Oxoid, Landsmeer, the Netherlands).
The colonies on the plates were counted after approximately 12 hours, and the
CFU/mL was calculated.
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In the co-cultures, P. aeruginosa growth was also monitored by CFU counting.
The counting was performed as described above and samples were taken every hour
from 1 to 9 hours, every 2 hours from 9 to 13 hours, every 4 hours from 13 to 25
hours and at 33 hours after adding P. aeruginosa to A. fumigatus.
4.2.3 Headspace sampling
For sampling the headspace of the cultures, a setup was used as described earlier
[11]. Briefly, all cultures were placed in an environmental chamber at 37 ◦C.
Cultures were constantly shaken on an orbital shaker (Sanyo orbital shaker, Osaka,
Japan) at 100 revolutions per minute (rpm) in silicon coated 250 mL round-bottom
Erlenmeyer flasks. Each flask was closed using a glass stopper. This stopper
contained two Teflon open-close valves acting as the inlet and outlet. Bacterial
filters were placed on the inlet and outlet of the flasks to prevent contamination.
The headspaces of the cultures were constantly flushed with 3.5 L/h of catalysed
compressed air.
To sample 3.5 litre of headspace, a glass tube filled with Tenax TA® (Shi-
madzu, Kyoto, Japan), was connected to the outlet of the glass stopper for 60
minutes. Sterile BHI broth, kept under the same environmental conditions as the
cultures, was used as a control experiment. The headspaces of the BHI broth
medium and the mono-cultures were sampled at 16, 24 and 48 hours after in-
oculation. In the co-culture, samples were taken at 16, 24 and 48 hours after
inoculation of the first pathogen, A. fumigatus. Each experiment was performed
independently 6 times using 2 technical replicates (n=12).
4.2.4 Headspace analysis
The headspace samples were analysed using thermal desorption (TD20) coupled to
QP2010 Ultra GC-MS (Shimadzu, Kyoto, Japan). After headspace sampling, the
Tenax tubes were flushed with 6 L/h nitrogen for 60 seconds, in a custom-made
setup, to dry the samples. Thereafter, the tubes were transported to a thermal
desorption unit where the tubes were heated to 250 ◦C for 8 minutes with a flow
of 60 mL/min for desorption of all trapped compounds. A cold trap at 10 ◦C cap-
tured the VOCs, and was subsequently heated to 250 ◦C to release the molecules
through a heated transfer line (split 1:20) at 260 ◦C onto a CP-Sil 19 CF capillary
column (25 m, 0.25 mm inner diameter, 1.2 m film thickness, Agilent Technologies
Netherlands BV, Amstelveen, The Netherlands) at 1.02 mL/min column flow. The
oven temperature profile started at 40 ◦C for 4 minutes, then increased to 250 ◦C
with a 5 ◦C/min heating rate, and finished with 14 minutes at 250 ◦C. Electron
ionization (EI) at 70 eV was used to ionize the molecules, and a quadrupole mass
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spectrometer detected the fragment ions in the mass to charge (m/z ) range of 30-
500 Da. Compounds were putatively identified based on 80% minimal similarity of
the MS spectra compared to the National Institute of Standards and Technology
(NIST) libraries NIST08 and NIST08s.
4.2.5 Standard compounds
The assignment of the VOC biomarkers resulted from the statistical analysis
was performed with standards with a purity of ≥ 96%. Dimethyl trisulfide, 2-
furaldehyde, methyl thiolacetate, 1-undecene and 2-nonanone were purchased from
Sigma Aldrich Chemie B.V., Zwijndrecht, the Netherlands, 2-octanone was pur-
chased from Acros Organics (Fisher Scientific, Landsmeer, the Netherlands) and
8-nonen-2-one from AKos GmbH, Steinen, Germany. The standards were diluted
10.000 times in either methanol (2-nonanone, 2-octanone, methyl thiolacetate,
dimethyl trisulfide and 8-nonen-2-one) or acetone (2-furaldehyde, 1-undecene) and
2 µL of this solution was injected onto the Tenax tube. To dry the samples, the
tubes were flushed with 6 L/h nitrogen for 60 seconds. The retention times (RTs)
and mass spectra of these pure standards were compared with those obtained in
the experimental samples to confirm the correct identification of the compound.
4.2.6 Multivariate analysis
Multivariate analysis by Partial Least Squares Discriminant Analysis (PLS-DA)
[12] was performed to identify VOC biomarkers for the presence of P. aeruginosa,
A. fumigatus or both. A separate PLS-DA model was fitted for each sampling
time point (16, 24 and 48h).
Partial Least Squares Discriminant Analysis makes linear combinations of the
Total Ion Current (TIC) of every VOC to form Latent Variables (LVs); consider-
ing compounds that were present in at least 50% of replicates per culture. This
analysis reduces the complexity of the data considerably and simultaneously de-
termines strong correlations between VOCs. These correlations are expressed in
loadings and scores. Loadings indicate the importance of each VOC on every LV,
while scores reflect the differences between the samples.
The scores and loadings were represented together in a two-dimensional biplot
[13] from which the relevance of each VOC to distinguish between culture types
can be interpreted in two dimensions.
To establish time-independent VOC biomarkers linked to the presence of one
or both pathogens, a group of selected VOCs was composed for each culture type
using all three models. The VOCs were ranked by analysing the loadings for their
positive contribution in the direction of each culture type. These VOC rankings
were multiplied over the three time points. The number of compounds to include
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was determined by comparing the rank products of all VOCs visualized in bar
graphs. One rank product threshold was set for all three culture types based on a
steep increase in rank product when including more VOCs. The VOC biomarkers
were represented in a Venn diagram [14]. The power of these time-independent
VOC biomarker combinations was determined using one PLS-based classifica-
tion model including all sampling time points. As an additional validation, a
PLS-DA model was made for each sampling time point using only these time-
independent VOC biomarker combinations. Furthermore, to test whether these
time-independent VOCs can successfully distinguish the presence of pathogens
from the culture medium at all-time points, a four-class PLS-DA model has been
constructed including the culture medium.
All PLS-DA models were fitted using double cross-validation [15]. To assess the
model performance on a test set, six-fold cross validation was used. An underlying
five-fold cross validation was used to determine the optimal number of LVs to
include for classification. This means that a model was built using 80% of all
samples, which was subsequently tested on the remaining 20% of the samples.
This was repeated for increasing numbers of LVs and the number with the highest
prediction accuracy (smallest amount of misclassified samples) was selected to fit
the final model. The final estimation of prediction accuracy was given as the mean
performance of the six cross-validation models. This resulted in a cross-table for
each of the three models showing the percentage of samples with correctly classified
culture type.
Multivariate data analysis was performed in Matlab R2014a (The MathWorks,
Inc., Natick, Massachusetts, USA). PLS-DA was performed using PLS Toolbox
7.8.2 (Eigenvector Research, Inc., Wenatchee, Washington, USA).
4.3 Results
4.3.1 Growth
The growth of A. fumigatus and P. aeruginosa was monitored in mono- and co-
cultures. During visual examination of A. fumigatus, less growth was observed
in the co-culture as compared to the mono-culture. The galactomannan levels
in the growth medium of mono-cultures of A. fumigatus increased linearly up to
20 hours, and increased faster than that after 24 hours. In the co-culture, the
galactomannan levels were found to be reduced compared to the A. fumigatus
mono-cultures, especially at 48 hours. Pseudomonas aeruginosa in mono-culture
shows a typical sigmoidal growth curve. The growth rate in co-culture was found
to be lower and the final CFU concentration was slightly lower (figure 4.1).
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Figure 4.1: (a): Galactomannan levels in A. fumigatus growth medium in mono-culture
(4) and co-culture (•). Data represent mean +/- SD (n=2). (b): growth curve of
P. aeruginosa in mono-culture (+) and in co-culture (•). Curve fitting with one phase
exponential association. CFU: colony forming units.
4.3.2 Headspace VOCs
We identified VOC profiles of P. aeruginosa, A. fumigatus and the co-culture
consisting of 104 compounds for each culture. The PLS score plots of the VOCs
produced by the three different culture types are shown in figure 4.2. At 16 hours
after inoculation of A. fumigatus (and 1 hour after inoculation of P. aeruginosa)
the profiles of A. fumigatus and P. aeruginosa were clearly separated (figure 4.2a),
with the co-culture profile partially overlapping with that of the A. fumigatus.
After 24 hours (figure 4.2b), the samples of three culture types were consistently
distinguished from one another. At 48 hours the co-culture profile moved towards
P. aeruginosa (figure 4.2c).
The PLS data analysis identified not a single, but a combination of VOC
biomarkers associated with P. aeruginosa, A. fumigatus and co-cultures at each
of the three time points (16, 24 and 48 hours after inoculation). The top ten VOC
biomarkers in these combinations are listed in table S1 (supplementary material).
We found specific VOC biomarker combinations for each sampling time point.
However, some individual VOCs are present at all time points. For example, 8-
nonen-2-one was found at all three time points in A. fumigatus and similarly,
2-nonanone was linked to co-culture. The VOC biomarker combinations of co-
cultures were distinct from those of mono-cultures.
As an example, a PLS biplot of the top five (out of top ten) of VOC biomarkers
for each of the culture types at 48 hours is presented in figure 4.3.
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Figure 4.2: PLS score plots of VOCs in the headspace of P. aeruginosa (+), A. fu-
migatus (4) and co-cultures (•), at 16 hours (a), 24 hours (b) and 48 hours (c) after
inoculation. Points represent experimental samples.
The VOC emissions varied over time within each culture type. We therefore
identified culture specific VOC biomarker combinations, which contain compounds
that are characteristic at all three time points. For these combinations, VOCs with
a rank product lower than 0.003 (rank 1 = highest position) were selected (figure
S1). As result, 14 compounds for P. aeruginosa, 10 compounds for A. fumigatus,
and 11 compounds for the co-culture were obtained and listed in table 4.1. A
graphical representation (Venn diagram) of these compounds is given in figure 4.4.
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Figure 4.3: PLS biplot of VOCs in the headspace of P. aeruginosa (+), A. fumigatus
(4) and co-cultures (•) at 48 hours after inoculation. For visualisation, only top 5 VOCs
are depicted (a list of top 10 VOC biomarker combination is provided in table S1). Letters
correspond to VOCs shown in the accompanying table.
We found 5 VOC biomarkers produced in mono-culture as well as in co-cultures;
1-undecene (α) and 3-methyl-1H-pyrrole (β) are present in both P. aeruginosa
and co-culture, while 2-tridecanone (γ), 2-undecanone (δ) and 2-nonanone (ε) are
detected in A. fumigatus and co-cultures. Six VOC biomarkers were revealed only
in the co-culture environment (T-Y).
Using the time-independent VOC biomarker combinations, the correct identi-
fication of a P. aeruginosa, A. fumigatus, or co-culture sample was predicted with
a probability of 89 %, 83 %, or 91 % respectively.
The biomarker combinations have been validated and a cross-table for the
three models showing the prediction accuracy of correct identification for each
culture type at each sampling time point was included in supplementary material
(table S3).
The cross-validation of the four-class PLS-DA model in which the medium
was included, demonstrates that the presence vs absence of pathogens based on
the time-independent VOC biomarker combinations can be predicted with a 100%
sensitivity (figure 4.5).
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Table 4.1: Time-independent combination of P. aeruginosa, A. fumigatus and co-
cultures, respectively. The list contains VOC biomarkers consistently present at 16,
24 and 48 hours after inoculation. Bold names are correctly identified based on compar-
ison with pure compound standards. One compound could not be identified (F). Letters
correspond to VOCs as shown in figure 4.4. Additional information on m/z and RT of
these compounds can be found in table S2.
P. aeruginosa A. fumigatus Co-culture
1. 2,3-dimethyl-5-
isopentylpyrazine
(A)
8-nonen-2-one (M) 2-nonanone (ε)
2. 2-methyl-3-(2-
propenyl)-pyrazine
(B)
2,3-dihydro-1,1,3-
trimethyl-3-phenyl-
1H-indene (N)
1-undecene (α)
3. methyl thiolacetate
(C)
2-tridecanone (γ) 2-ethyl-benzenamine
(T)
4. 2-furaldehyde (D) 1-methylethenyl-
pyrazine (O)
2-undecanone (δ)
5. dimethyl trisulfide
(E)
azacyclotridecan-2-one
(P)
2-hexanone (U)
6. unidentified (F) 2-ethenyl-5-methyl-
pyrazine (Q)
3-methyl-1H-pyrrole
(β)
7. tetradecane (G) 2-undecanone (δ) 2-tridecanone (γ)
8. 1-undecene (α) 2-nonanone (ε) 3-methyl-3-penten-2-
one (V)
9. hexanal (H) 1-hydroxy-2-
propanone (R)
4-methyl-3-penten-2-
one (W)
10. 6-tridecane (I) 2-acetylthiazole (S) 1-propanol (X)
11. dimethyl disulfide (J) 2-octanone (Y)
12. butanal (K)
13. 3-methyl-1H-pyrrole
(β)
14. 2-methyl-butanal (L)
54
44.3. Results
Figure 4.4: Venn diagram of the time-independent VOC biomarker combinations for
P. aeruginosa, A. fumigatus and co-cultures. Letters correspond to VOCs as described
in table 4.1.
Figure 4.5: PLS scoreplot of time-independent VOC biomarker combinations in the
headspace of P. aeruginosa (+), A. fumigatus (4), co-cultures (•) and culture medium
().
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4.4 Discussion
We investigated the suitability of GC-MS with dedicated multivariate discriminant
analysis to identify unique VOC biomarkers emitted by P. aeruginosa and A. fumi-
gatus mono-cultures and their co-cultures in vitro. We determined whether these
VOCs were consistent over time and/or whether they changed in a co-culture en-
vironment compared to mono-cultures. Additionally, the growth of P. aeruginosa
and A. fumigatus in mono- and in co-culture was determined.
We found VOC biomarker combinations associated with the presence of P. aerug-
inosa, A. fumigatus mono- and co-culture at three sampling time points. As the
measurement progresses, the cultures undergo obvious changes, such as reduction
in availability of nutrients, build-up of waste products and increases in population
density, implicit in quorum sensing. Therefore, we postulate that the changes in
VOC emissions may be related to these processes.
The co-culture VOC profile differs from the ones of mono-cultures, indicating
that there is an interaction between the two pathogens. Specifically, the co-culture
profile in the early stage (16h) showed similarity with the profile of A. fumigatus
rather than of P. aeruginosa. However, this changed over time and moved towards
P. aeruginosa in a later stage (48h), indicating that P. aeruginosa eventually
dominates the co-culture. This is also evident from the quantitative cultures.
In co-culture the growth of A. fumigatus is blunted after 16 hours, whereas the
growth of P. aeruginosa was slightly slower. Several co-culture replicates taken
after 48h are indistinguishable from P. aeruginosa, indicating the co-culture is
completely dominated by the P. aeruginosa. Competition between P. aeruginosa
and A. fumigatus has been reported previously. Pseudomonas aeruginosa is an
opportunistic pathogen, which is able to produce detectable levels of the toxic
compound hydrogen cyanide (HCN) in vitro [11, 16-18]. This might inhibit the
growth of other pathogens such as A. fumigatus [19]. Moreover, pyocyanin and
other phenazines, also produced by P. aeruginosa, are reported to inhibit fungal
growth [20, 21]. Additionally, biofilm formation by A. fumigatus was found to
be inhibited by the presence of P. aeruginosa, indicating that P. aeruginosa can
influence fungus growth in vitro [22].
Different studies report on VOC emission by P. aeruginosa [16, 18, 23-29] or
A. fumigatus in vitro [30-34]. However, most of these studies focus only on the
VOC production at one specific time point. Only Filipiak et al. [25] presented
data at more time points for P. aeruginosa, and Chippendale et al. [35] for A. fu-
migatus in mono-culture and in co-culture with P. aeruginosa. There are three
main aspects that differentiate this latest study from ours. Firstly, using selected
ion flow tube - mass spectrometry, a range of VOC emissions between m/z 10-180
from mono-cultures of A. fumigatus and co-cultures with P. aeruginosa were mon-
itored at 24, 48 and 72 h, respectively. In contrast, we investigated a broad range
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of VOCs (m/z 30-500) detectable with TD combined with GC-MS, in both mono-
and co-cultures of P. aeruginosa and A. fumigatus. Secondly, we focused on most
discriminative compounds in mono-cultures of P. aeruginosa and A. fumigatus, as
well as in co-cultures, whereas Chippendale et al. investigated whether produc-
tion of specific VOCs has been modified in a co-culture environment as compared
to mono-cultures of A. fumigatus. Thirdly, the compounds that were altered in
cultures relative to media prior to principal component analysis (PCA) were ex-
cluded in Chippendale et al., while we considered all VOCs detected in headspace
of the cultures for PLS-DA analysis, without discarding those from the medium.
Out of the 30 VOCs present in the time-independent biomarker combinations, 15
were also detected in the medium headspace (data not shown). Most of these
compounds were consumed differently by the mono- and co-cultures, suggesting a
different metabolism and/or competition. We consider the medium for cultures as
an integral part of the microbiological ecosystem, hence we included all VOCs from
the headspace, without subtracting or discarding the medium-specific compounds.
Chippendale et al. identified compounds present in the A. fumigatus mono-
culture as well as in co-culture with P. aeruginosa at 24, 48 and 72 hours after
inoculation. Furthermore, a study by Zhu et al. [28] reported that the individual
pathogens can still be identified in mixed cultures of S. aureus and P. aeruginosa,
based on similar compounds released. Our results confirmed that some compounds
found in mono-culture are also detectable in co-culture (VOC biomarker α-ε in
figure 4.4/ table 4.1). Furthermore, we found VOC biomarkers specific for co-
cultures (T-Y in figure 4.4/ table 4.1), and compounds present in mono-culture
that vanish in co-culture after 48h (data not shown).
Although we are presenting multivariate analysis and the individual com-
pounds within the VOC biomarker combinations do not necessarily have individual
discriminative power, it is interesting to have a look at few of these VOC biomark-
ers. For example, the rank 1 VOC biomarkers in these combinations have been
reported previously in pathogen-related studies. Methyl thiolacetate (or S-methyl
thioacetate) present in P. aeruginosa cultures, was also found in the headspace of
Clostridium spp. [36] and of Haemophilus influenza, another pathogen frequently
infecting CF patients [37]. The compound 8-nonen-2-one was detected at three
time points in A. fumigatus mono-cultures and in co-cultures. This indicates that
the production of this compound is independent of growth of A. fumigatus. Fur-
thermore, it looks to be specific for A. fumigatus, since it was detected only in one
sample of P. aeruginosa, at 16 hours. The compound 8-nonen-2-one is found in
mould-ripened cheeses [38-40] but has not been described previously as present in
the headspace of A. fumigatus samples in vitro. 2-Nonanone has been previously
detected in P. aeruginosa headspace [25-27], and in sputum of P. aeruginosa in-
fected CF patients [27, 41]. In our study, P. aeruginosa also produced 2-nonanone,
but with a higher rank than 10 and therefore has not been included in the VOC
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biomarker combination. However, it is present in the VOC biomarkers for A. fumi-
gatus and co-cultures. Noticeable, the production of this compound was enhanced
in co-culture as compared to mono-cultures.
Also other compounds from the VOC biomarker combinations found in this
study have been previously described. 1-Undecene has been reported as a potential
biomarker for P. aeruginosa in mono-culture [26]. In addition, this study shows
that this compound is also produced in a co-culture environment. 2-Pentylfuran
has been proposed by other studies as a potential biomarker for detecting A. fu-
migatus [34, 42]. However, we did not detect this compound in any of the A. fu-
migatus mono-culture and co-culture samples we tested. We checked whether our
system was able to detect 2-pentylfuran by injecting the pure compound on Tenax
tubes and by adding the pure compound to medium and subsequently sampling
the headspace. In both experiments 2-pentylfuran was detected and identified cor-
rectly by GC-MS (data not shown). Thus, it is likely that 2-pentylfuran was not
produced, or the production in our A. fumigatus cultures was below the detection
limit of the instrument. The absence of 2-pentylfuran is in accordance with a
study performed by Bazemore et al. [43]. Possible explanations for this difference
may be the use of other fungal strains and/or different culturing medium and sam-
pling time points. However, if 2-pentylfuran is not detectable in all A. fumigatus
strains, the strength and usefulness of this compound as a single biomarker for
A. fumigatus is limited. In addition, 2-pentylfuran is found in common foods and
may therefore be less suitable as a pathogen-specific biomarker in a breath test
[44, 45].
It is generally accepted that one specific compound might not be sufficient
to correctly predict the presence of a pathogen [25, 46, 47]. Using multivariate
analytical tools, we could successfully determine VOC biomarker combinations
that offer a good accuracy for the identification of both mono-cultures and co-
culture. Furthermore, we have demonstrated that the presence or absence of the
pathogens can be 100% predicted with a four-class PLS-DA model including the
VOCs from the time-independent biomarker combinations. Further studies need
to be performed to validate these findings in a broader context, such as comparing
different culture media.
Although these data cannot be directly extrapolated to the in vivo situation
[48], it is definitely promising for the development of a future breath test. In order
to know the clinical relevance of the presented results, clinical validation is neces-
sary. A different environment, the presence of other pathogens [49, 50], antibiotic
therapy [11] and stage of infection might all influence the VOC combinations. It is
clear that both organisms interact, which will result in changes in the individual
VOC production.
In summary, we could identify specific VOC biomarker combinations for P.
aeruginosa, A. fumigatus and co-cultures in vitro. This study demonstrates that
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VOC combinations of P. aeruginosa and A. fumigatus in mono-cultures are dif-
ferent from the VOC combination in co-cultures, and that all these biomarker
combinations are time dependent. However, using PLS-DA, we determined time-
independent VOC biomarker combinations, which can be interesting for future
detection of pathogens in exhaled breath of CF patients.
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Table S1: Top ten VOCs produced by P. aeruginosa, A. fumigatus and co-cultures,
16, 24 and 48 hours after inoculation including their mass to charge ratio and retention
time (m/z − RT). Bold names are correctly identified based on comparison with pure
compound standards (maximum difference in RT: 0.1 minute (0.1%) and a 90-95% MS
match score, between chemical standards and biological samples). Other compounds are
tentatively identified.
P. aeruginosa A. fumigatus Co-culture
16 h
1. 2-furaldehyde (96 − 16.1) 8-nonen-2-one (43 − 23.4) 2-octanone (43 − 18.8)
2. butanal (44 − 5.2) 2-tridecanone (58 − 34.5) 2-nonanone (58 − 22.2)
3. tetradecane (57 − 29.3) 2-nonanone(58 − 22.2) 2-hexanone (43 − 12.7)
4. α,α-dimethyl-
benzenemethanol (43 − 24.7)
7-decen-2-one (43 − 29.3) 2-undecanone (58 − 28.3)
5. 2-methyl-3-(2-propenyl)-
pyrazine (133 − 23.3)
1-propanol (31 − 5.1) 1-undecene (70 − 20.5)
6. heptanal (70 − 16.7) azacyclotridecan-2-one
(100 − 43.2)
2-pentanone (43 − 5.6)
7. isothiocyanato-cyclohexane
(55 − 28.7)
2-undecanone (58 − 28.3) 2-heptanone (43 − 16.5)
8. hexanal (44 − 12.9) ethyl acetate (43 − 5.4) 7-decen-2-one (43 − 29.3)
9. thiazole (85 − 10.9) 3-hydroxy-2-butanone
(45 − 11.5)
2-tridecanone (58 − 34.5)
10. 2,3-dimethyl-5-
isopentylpyrazine (122 − 29.2)
2-acetylthiazole (43 − 22.1) 2-ethyl-benzenamine
(106 − 27.0)
24 h
1. dimethyl trisulfide
(126 − 19.0)
8-nonen-2-one (43 − 23.4) 1-undecene (70 − 20.5)
2. unidentified (62 − 2.9) 2,3-dihydro-1,1,3-trimethyl-
3-phenyl-1H-indene
(221 − 39.9)
1-undecene (70 − 20.5)
3. 1-undecene (70 − 20.5) 3-methyl-2-butanone
(43 − 5.7)
2-ethyl-benzenamine
(106 − 27.0)
4. methyl thiolacetate
(43 − 8.5)
1-methylethenyl-pyrazine
(120 − 20.9)
2-undecanone (58 − 28.3)
5. 6-tridecane (67 − 20.7) ethenyl-pyrazine (106 − 18.0) 6-methyl-5-hepten-2-
one(43 − 20.0)
6. dimethyl disulfide (94 − 10.1) heptanal (44 − 16.7) 1-propanol (31 − 5.1)
7. 2,3-dimethyl-5-
isopentylpyrazine (122 − 29.2)
2-ethenyl-5-methyl-pyrazine
(120 − 21.0)
3-methyl-2-butenal
(84 − 13.6)
8. 2-methyl-propanal (43 − 4.2) thiazole (85 − 10.9) 2-nonanone (58 − 22.2)
9. 3-methyl-1H-pyrrole
(80 − 17.0)
azacyclotridecan-2-one
(100 − 43.2)
8-nonen-2-one (43 − 23.4)
10. 2-methyl-butanal (44 − 4.5) 2-undecanone (58 − 28.3) 1,4-pentadiene (67 − 2.5)
48 h
1. methyl thiolacetate
(43 − 8.5)
8-nonen-2-one (43 − 23.4) 2-nonanone (58 − 22.2)
2. 2,3-dimethyl-5-
isopentylpyrazine (122 − 29.2)
hexadecane (57 − 34.4) 3-methyl-3-penten-2-one
(55 − 14.9)
3. 2-methyl-3-(2-propenyl)-
pyrazine (133 − 23.3)
2,3-dihydro-1,1,3-trimethyl-
3-phenyl-1H-indene
(221 − 39.9)
4-methyl-3-penten-2-
one(83 − 13.0)
4. 3-methyl-1H-pyrrole
(80 − 17.0)
1-methylethenyl-pyrazine
(120 − 20.9)
2-ethoxy-benzenamine
(137 − 29.4)
5. 6-tridecane (67 − 20.7) heneicosane (57 − 36.7) 2-ethyl-benzenamine
(106 − 27.0)
6. decyl-oxirane (71 − 28.7) undecanal (43 − 29.5) 1-propanol (31 − 5.1)
7. unidentified (62 − 2.9) 2-ethenyl-5-methyl-pyrazine
(120 − 21.0)
methyl ester thiocyanic acid
(73 − 11.8)
8. methyl ester thiocyanic acid
(73 − 11.8)
2-acetylthiazole (43 − 22.1) 2-methyl-1-butanol
(56 − 11.4)
9. 2-methyl-1-butanol (56 − 11.4) 2-tridecanone (58 − 34.5) 2-tridecanone (58 − 34.5)
10. 4-methyl-3-penten-2-one
(83 − 13.0)
azacyclotridecan-2-one
(86 − 43.2)
3-hydroxy-2-butanone
(45 − 11.5)
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Table S2: Time-independent combination of P. aeruginosa, A. fumigatus and co-
cultures, respectively. The list contains VOC biomarkers consistently present at 16,
24 and 48 hours after inoculation, including their mass to charge ratio and retention
time (m/z − RT). Bold names are correctly identified based on comparison with pure
compound standards (maximum difference in RT: 0.1 minute (0.1%) and a 90-95% MS
match score, between chemical standards and biological samples). The other compounds
are tentatively identified.
P. aeruginosa A. fumigatus Co-culture
1. 2,3-dimethyl-5-
isopentylpyrazine
(122 − 29.2 )
8-nonen-2-one
(43 − 23.4 )
2-nonanone
(58 − 22.2 )
2. 2-methyl-3-(2-
propenyl)-pyrazine
(134 − 23.3 )
2,3-dihydro-1,1,3-
trimethyl-3-
phenyl-1H-indene
(221 − 39.9 )
1-undecene
(70 − 20.5 )
3. methyl thiolacetate
(43 − 8.5 )
2-tridecanone
(58 − 34.5 )
2-ethyl-benzenamine
(106 − 27.0 )
4. 2-furaldehyde
(96 − 16.1 )
1-methylethenyl-
pyrazine
(120 − 20.9 )
2-undecanone
(58 − 28.3 )
5. dimethyl trisulfide
(126 − 19.0 )
azacyclotridecan-2-one
(100 − 43.2 )
2-hexanone
(43 − 12.7 )
6. unidentified (62 − 2.9 ) 2-ethenyl-5-methyl-
pyrazine (120 − 21.0 )
3-methyl-1H-pyrrole
(80 − 17.0 )
7. tetradecane
(57 − 29.3 )
2-undecanone
(58 − 28.3 )
2-tridecanone
(58 − 34.5 )
8. 1-undecene
(70 − 22.5 )
2-nonanone
(58 − 22.2 )
3-methyl-3-penten-2-
one (55 14.9 )
9. hexanal (44 − 12.9 ) 1-hydroxy-2-
propanone (74 − 10.0 )
4-methyl-3-penten-2-
one (83 − 13.0 )
10. 6-tridecane
(67 − 20.7 )
2-acetylthiazole
(43 − 22.1 )
1-propanol (31 − 5.1 )
11. dimethyl disulfide
(94 − 10.1 )
2-octanone
(43 − 18.8 )
12. butanal (44 − 5.2 )
13. 3-methyl-1H-pyrrole
(80 − 17.0 )
14. 2-methyl-butanal
(44 − 4.5 )
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Table S3: Prediction of correct classification of a culture type after 16, 24 and 48 hours
using the time-independent VOC biomarker combinations generated by PLS-DA.
Culture type
Predicted as
P. aeruginosa
(%)
Predicted as
A. fumigatus
(%)
Predicted as
Co-culture
(%)
16h P. aeruginosa 100 0 0
A. fumigatus 0 75 25
Co-culture 0 18.2 81.8
24h P. aeruginosa 91.7 0 8.3
A. fumigatus 0 100 0
Co-culture 8.3 0 91.7
48h P. aeruginosa 83.3 0 16.7
A. fumigatus 0 100 0
Co-culture 0 0 100
Figure S1: Bar graphs showing the rank products of the time-independent VOCs pro-
duced consistently at 16, 24 and 48 hours after inoculation, by P. aeruginosa, A. fumi-
gatus mono- and co-culture. Considering a 0.003 rank product threshold, 14, 11 and 10
compounds were selected for P. aeruginosa, A. fumigatus and co-culture, respectively.
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Detection of Staphylococcus aureus in cystic
fibrosis patients using breath VOC profiles
5
Staphylococcus aureus (S. aureus) is a common bacterium infecting children with
cystic fibrosis (CF). Since current detection methods are difficult to perform in
children, there is need for an alternative. This proof of concept study investi-
gates whether breath profiles can discriminate between S. aureus infected and
non-infected CF patients based on volatile organic compounds (VOCs). We col-
lected exhaled breath of CF patients with and without S. aureus airways infec-
tions in which VOCs were identified using gas chromatography - mass spectrom-
etry. We classified these VOC profiles with sparse Partial Least Squares - Dis-
criminant Analysis. Multivariate breath VOC profiles discriminated infected from
non-infected CF patients with high sensitivity (100%) and specificity (80%). We
identified the nine compounds most important for this discrimination and suc-
cessfully detected S. aureus infection in CF patients, using breath VOC profiles.
Nine highlighted compounds can be used as a focus point in further biomarker
identification research. The results show considerable potential for non-invasive
diagnosis of airway infections.
Accepted for publication in Journal of Breath Research
69
5Chapter 5. Detection of Staphylococcus aureus in breath
5.1 Introduction
Respiratory infections are the main problem in patients with cystic fibrosis (CF),
since they result in progressive loss of lung function and eventually death [1].
Staphylococcus aureus (S. aureus) is one of the most common bacteria infecting
children with CF. On average, 68 % of patients with CF are infected with S. au-
reus (including people with methicillin-resistant Staphylococcus aureus (MRSA)
infection) [2]. The prevalence of S. aureus infection peaks at almost 80% in six- to
ten-year old patients [3]. Early detection of respiratory infections is essential for
adequate treatment, but currently available detection methods are difficult to per-
form in children, time consuming, invasive (bronchoalveolar lavage), non-specific
(chest X-ray) or insensitive and unpleasant (sputum induction) [3-6]. For this rea-
son, a non-invasive, easy, fast and accurate method to detect respiratory infections
is needed.
One alternative approach could be the analysis of exhaled breath. Up till now,
potential markers for S. aureus detection in vitro are reported to be isovaleric
acid and methylbutanal [7,8]. Other compounds elevated in S. aureus headspace
are ammonia, methanol, acetaldehyde, ethanol, propanol and pentanal [9], as
well as butanol, acetic acid [10], acetone [10,11], 2-methylbutanal, benzaldehyde,
2,3-butanedione, 1-methyl-4-(1-methylethenyl)cyclohexane, dimethyldisulfide and
dimethyltrisulfide [11], 3-methyl-butanal [11,12], and 3-methyl-1-butanol, butanoic
acid and 3-methyl-butanoic acid [12]. However, these compounds are also found
in the headspace of other pathogens [7-9, 12-16], and are therefore not specific for
S. aureus. In vivo, acute S. aureus infection was detected in a bacterial murine lung
infection model, in an untargeted metabolomics study using secondary electrospray
ionization-mass spectrometry (SESI-MS) breath profiles [17]. Furthermore, S. au-
reus-derived metabolites could be detected in ventilator-associated pneumonia in
intensive care patients, in a recent prospective pilot study [18]. However, to our
knowledge, in vivo studies for detection of S. aureus in exhaled breath of CF
patients have not been performed yet.
Therefore, the aim of this proof of concept study was to investigate whether we
can discriminate between S. aureus infected and non-infected CF patients based on
Volatile Organic Compounds (VOCs) in their exhaled breath. For this purpose,
we used Gas Chromatography - Mass Spectrometry (GC-MS) for breath VOC
analysis, in combination with sparse Partial Least Squares Discriminant Analysis
(s-PLS-DA) for multivariate discrimination between the different patient groups.
5.2 Materials and Methods
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5.2.1 Subjects
Cystic fibrosis patients (≥ 6 years old) were recruited between January 8 and
July 16, 2015, from the outpatient clinic of Radboud University Medical Center -
Amalia Childrens Hospital, Nijmegen, the Netherlands. This study was approved
by the local medical ethics committee (CMO - Nijmegen/Arnhem) which waived
written informed consent. Oral consent was obtained from both participants aged
12 years and older, and from parents of children aged 6-18 years.
Non-smoking CF patients with and without S. aureus infection were included
in this study (table 5.1). Infection was defined as culturing S. aureus in sputum
(or cough swab sample for children unable to expectorate), on the day of breath
sampling or in ≥50% of the samples (minimum of 4 samples) over the previous
12 months. Free of infection was defined as S. aureus negative over the previous
12 months (minimum of 4 samples). Samples were obtained as a part of routine
clinical care.
Table 5.1: Patient characteristics by Staphylococcus aureus infection status.
Patient
number
Gender
Age
(years)
S. aureus
infection
Other infections
1 female 6 yes -
2 female 7 yes -
3 female 9 yes -
4 female 13 yes Serratia marcescens
4 female 13 yes Pseudomonas aeruginosa
5 female 21 yes Pseudomonas aeruginosa and
yeast
6 female 23 yes Haemophilus influenzae
7 male 8 yes -
8 male 9 yes Haemophilus influenzae
9 male 11 yes -
10 male 12 yes Haemophilus influenzae
11 male 16 yes -
12 male 19 yes -
13 male 54 yes Haemophilus influenzae
14 female 7 no -
15 female 7 no -
16 male 19 no Stenotrophomonas maltophilia
and Aspergillus fumigatus
17 male 7 no -
18 male 7 no -
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5.2.2 Breath sampling
All patients followed the same procedure for breath collection. After rinsing their
mouth with water, two breath samples were collected in 3L Tedlar bags (ProCare
B.V., Groningen, The Netherlands) at a constant flow rate of 50 mL s−1, using a
commercial breath sampler (Loccioni, Angeli di Rosora, Italy) [19]. Each breath
sample consisted of two mouth-exhalations through a bacterial filter (Air Safety
Limited, Lancashire, UK) and a non-rebreathable T-piece (Vacumed, Ventura,
USA) which were connected to a CO2 sensor and a calibrated buffer pipe. From the
total exhalation through the pipe, the first 150 mL of each exhalation was discarded
in a separate small bag, and the remaining part collected in the sampling bag. The
four exhalations were separated by 90 seconds, and at the same time, one sample
of ambient air was collected. Equal volumes of breath and ambient air samples
were stored within 6 hours on glass tubes filled with Tenax TA (Shimadzu, Kyoto,
Japan), using a custom-made pump box at 3 L/h. This volume was determined
by the lowest breath sample volume for each individual.
5.2.3 Breath analysis
Samples were analysed using thermal desorption (TD20) coupled to QP2010 Ultra
GC-MS (Shimadzu, Kyoto, Japan) as described earlier [16]. Briefly, the tubes
were dried in a custom-made setup at room temperature and thereafter heated in
a thermal desorption unit for desorption of all trapped compounds. A cold trap
captured the VOCs, and was subsequently heated to release the molecules through
a heated transfer line (split 1:10) onto a CP-Sil 19 CF capillary column (25 m,
0.25mm inner diameter, 1.2 m film thickness, Agilent Technologies Netherlands
BV, Amstelveen, the Netherlands). Helium was used as the carrier gas, at a flow-
rate of 1.02 ml/min. The GC temperature program started isothermal at 40 ◦C for
4 minutes and was then ramped to 250 ◦C with a 5 ◦C/min heating rate. Finally,
the temperature was kept isothermal at 250 ◦C for 14 minutes. After ionization
of the molecules by electron impact, a quadrupole mass spectrometer detected
nominal mass spectra with a scan rate of 20.000 amu/second. This resulted in
data comprising of retention times (RTs) in a range 0 - 60 minutes (11900 data
points) and mass spectra in a range m/z 30-500, for each sample.
5.2.4 Compound identification
The compounds were putatively identified by comparing the experimental spectra
with those of the National Institute for Standards and Technology (NIST) libraries
NIST08 and NIST08s (80% minimal similarity). The assignment of the compounds
most discriminating in the statistical analysis was performed with standards with
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a purity of ≥ 96% as described earlier [16]. The RTs and mass spectra of these
pure standards were compared with those obtained in the experimental samples
to confirm the correct identification of the compound (maximum difference in RT:
0.2% and a 90-95% MS match score, between chemical standards and biological
samples). The compounds 1,4-pentadiene, hexanal, 2-methyl-naphthalene and iso-
propyl myristate were purchased from Sigma Aldrich Chemie BV, Zwijndrecht, the
Netherlands, ethanol was purchased from Merck KGaA, Darmstadt, Germany, 2-
butanone was purchased from Merck Schuchardt, Hohenbrunn, Germany, acetone
was purchased from VWR International BV, Amsterdam, the Netherlands, and 3-
hydroxy-2-butanone was purchased from Thermo Fisher Scientific Inc, Karlsruhe,
Germany. The standards were diluted 10,000 times in methanol (ethanol, acetone,
2-butanone, 3-hydroxy-2-butanone, hexanal, undecane, 2-methylnaphthalene, iso-
propyl myristate) or acetone (1,4-pentadiene) and 2 µL of this solution was injected
onto the Tenax tube. Subsequently, the tubes were dried as described above and
heated in the thermal desorption unit.
5.2.5 Multivariate analysis
Data preprocessing
The VOC data obtained was preprocessed using MetAlign [20] and subsequently
using MSClust [21]. During preprocessing with MetAlign, the data underwent
baseline correction, denoising, alignment and peak picking, i.e. molecular features
extraction. During preprocessing with MSClust, molecular features from MetAl-
ign were grouped together into clusters corresponding to the same compounds.
Detailed settings of MetAlign and MSclust are available upon request. Oxygen
and clusters attributed to Tedlar and Tenax (phenol, N,N-dimethylacetamide, and
siloxane compounds) were removed from the data prior to analysis [22-24].
Samples were normalized by Probabilistic Quotient Normalization (PQN) [25],
a recommended method for normalization of chromatographic data [26]. Intensi-
ties of compounds were averaged for the duplicate breath samples. Correction for
background concentrations of compounds in ambient air was performed by calcu-
lating alveolar gradients [27]: subtracting the corresponding ambient air sample
from each average of two breath samples.
Discriminant analysis
Multivariate discriminant analysis was performed on the VOC profiles with sparse
Partial Least Squares Discriminant Analysis (s-PLS-DA) [28] to discriminate S. au-
reus infected from non-infected CF patients. Partial Least Squares is an estab-
lished method for dimension reduction. It does this by constructing latent variables
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(LVs), which are a relatively low number of linear combinations of all original vari-
ables (compounds). Sparse PLS integrates a variable reduction into this analysis
by selecting a limited number of compounds to be represented in a LV [29].
Two parameters need to be optimized in s-PLS-DA, being the number of LVs
in the PLS-DA model and the sparsity level that determines the maximum num-
ber of compounds that may contribute to each LV. These parameters were opti-
mized simultaneously using double cross-validation [30]. Within this validation,
an inner cross-validation, consisting of 5-fold cross-validation repeated 50 times,
determined the optimal combination of number of LVs and sparsity level. The
model performance was then determined by an outer cross-validation, also con-
sisting of a 5-fold cross-validation repeated 50 times, as the median percentage
of misclassified samples per class in all 50 repetitions. For cross-validation, sam-
ples were divided randomly, although stratified such that each test and training
set contained at least one sample from each patient group. The overall optimal
sparsity level was chosen to be the median of all optimal sparsity levels from the
cross-validation models. The overall optimum number of LVs was taken to be the
median number of LVs chosen for this optimal sparsity level. The statistical sig-
nificance of the model performance was assessed by a permutation analysis with
1000 realizations using the optimal settings, in which the original class labels were
randomly permuted. Compound importance was evaluated by the frequency of
compound selection in different cross-validations and repetitions. If a compound
was selected in at least 80% of all models, it was assumed to be relevant for the
detection of S. aureus infection. For these compounds, the median intensities in
S. aureus infected patients were compared to those in non-infected patients, to
evaluate whether their concentrations were elevated or reduced. A Wilcoxon rank
sum test was used to evaluate the difference between infected and non-infected
patients for each of these compounds in a univariate manner. The threshold for
significance was corrected for multiple testing using the Bonferroni correction [31]
for an overall critical value of α=0.05.
With the exception of MetAlign and MSclust, all algorithms used in this pa-
per are coded and executed in MATLAB version 8.3.0 (Mathworks, Natick MA).
Sparse-PLS code was made available by Szyman´ska et al. [32].
5.3 Results
We included 13 CF patients infected with S. aureus (10 with S. aureus on the
day of breath sampling, and 3 with S. aureus in ≥50% of their samples in the
previous 12 months) and 5 CF patients free from S. aureus infection (table 5.1).
One patient infected with S. aureus participated twice in the study, with 4 months
in between sampling dates. It is very well possible for a patient to develop different
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infections in this period. Since this patient suffered from different infections during
participation (see table 5.1, patient number 4), the breath profile is expected to
differ significantly, and therefore these samples were treated as independent. This
resulted in 19 measurement sessions with 2 breath samples each. The median
[interquartile range (IQR)] age in the S. aureus infected group was 13 [9 to 20]
compared to 7 [7 to 13] in the group free from S. aureus infection.
Figure 5.1: The average GC chromatogram of VOCs in exhaled breath of a S. aureus
(a) non-infected and (b) infected CF patient. The horizontal axis represents the reten-
tion time in minutes. The vertical axis (zoomed in to show also smaller peaks) shows
the intensity (total ion current) of the compounds present in the sample. Arrows indi-
cate peaks attributed to sample collection and adsorbent materials: phenol (24.6 min),
N,N-dimethylacetamide (18.3 min), and siloxane compounds (21.6, 26.6, and 31.2 min).
Letters correspond to compounds listed in table 5.2.
Chromatograms were obtained for all breath and ambient air samples. The
mean breath GC chromatograms (on a point-by-point basis) of S. aureus infected
and non-infected CF patients before preprocessing are shown in figure 5.1. All
peaks were within the linear range of the detector. Small differences can be ob-
served between these chromatograms. The area between 15 and 35 minutes con-
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tains the most peaks. Five peaks, indicated with arrows, were attributed to com-
pounds related to sample collection and adsorbent materials (Tedlar and Tenax,
respectively)[22-24]. These peaks were removed prior to data analysis. Breath
VOC profiles of S. aureus infected CF patients differ from those of non-infected
patients. s-PLS-DA resulted in a median sensitivity of 100% and a specificity of
80.0%. Permutation testing showed that this prediction was significant (p<0.001).
The optimal parameter settings for s-PLS-DA were a sparsity level of 4 with 9 LVs.
The most important VOCs responsible for separation of infected and non-
infected patients were identified as 1,4-pentadiene, ethanol, acetone, 2-butanone,
3-hydroxy-2-butanone, hexanal, undecane, 2-methyl-naphthalene and isopropyl
myristate, and are listed in table 5.2. The VOCs are correctly identified based
on comparison with pure compound standards. As measure of importance, the
frequency (expressed as a percentage) in which each compound was selected dur-
ing cross-validation was determined. Ion counts of six compounds were elevated in
concentration in S. aureus infected compared to non-infected patients, and reduced
in concentration for three compounds. The significance threshold for the Wilcoxon
rank sum test, after correcting for multiple testing, is α=0.0056 (=0.05/9). The
compound undecane showed significant difference between non-infected and in-
fected patients (p=0.0050).
Table 5.2: Nine VOCs important for discrimination of S. aureus infected from non-
infected CF patients, including their mass to charge ratio (m/z ) and retention time (RT)
in minutes, using mean values determined in breath samples. The frequency in which
each compound was selected during cross-validation is listed in the fifth column. The
sixth column indicates whether the compound was elevated (↑) or reduced (↓) in S. aureus
infected compared to non-infected CF patients. Column seven provides the p-values from
the Wilcoxon rank sum test.
RT m/z Name %
Elevated (↑)
or reduced (↓) p-value
A 2.5 68 1,4-pentadiene 100 ↑ 0.010
B 2.8 46 ethanol 84.0 ↑ 0.34
C 3.2 58 acetone 85.6 ↑ 0.014
D 5.4 74 2-butanone 80.0 ↑ 0.50
E 11.5 88 3-hydroxy-2-butanone 100 ↓ 0.50
F 12.7 100 hexanal 90.4 ↓ 0.69
G 13.6 156 undecane 81.2 ↑ 0.0050
H 30.0 142 2-methylnaphthalene 83.2 ↑ 0.75
I 40.8 270 isopropyl myristate 99.2 ↓ 0.087
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5.4 Discussion and conclusion
In this study, we investigated whether it was possible to discriminate S. aureus
infected from non-infected CF patients based on VOCs in exhaled breath. Breath
VOC profiles allowed successful detection of S. aureus infection, and this resulted
in a shortlist of nine compounds important for the discrimination of the two patient
groups. These nine compounds were correctly identified based on comparison with
pure compound standards.
Previous studies have shown the potential of metabolomics of VOCs in exhaled
breath of CF patients. Robroeks et al. [33] identified CF patients with or without
positive Pseudomonas aeruginosa (P. aeruginosa) cultures 100% correctly using
Multiple Discriminant Analysis (MDA), by means of fourteen VOCs in exhaled
breath. However, they did not report the molecular identity of those compounds.
In addition, MDA builds a model using all measured compounds, many of which
are possibly unrelated to P. aeruginosa infection. Including these compounds
could weaken the discrimination power of the method and add noise to the model
[34]. This also means that the trend of interest might be masked by irrelevant
trends in the data (e.g. related to diet or physical activity) [35]. Sparse PLS-DA
reduces these risks and facilitates biological interpretation by including only the
most important compounds.
We identified the nine most discriminating compounds for S. aureus infection
in CF patients. Almost all of these compounds have been reported previously ei-
ther in bacterial headspace or in exhaled breath. The compounds 1,4-pentadiene,
ethanol, acetone, 2-butanone, undecane and 2-methylnaphthalene were found to be
elevated in S. aureus infected patients compared to non-infected. The compounds
3-hydroxy-2-butanone, hexanal and isopropyl myristate were reduced. One possi-
ble explanation for this would be uptake of these compounds by S. aureus bacteria.
Additional research is required to investigate this.
Univariate analysis of the nine important compounds indicated undecane as
significant, and, although undecane was also reported as a characteristic VOC in
exhaled breath of lung cancer patients [36] and of chronic obstructive pulmonary
disease (COPD) patients [37], and its use as a single biomarker deserves atten-
tion in further research. Analysis also revealed low p-values for 1,4-pentadiene,
acetone and isopropyl myristate. The other compounds had relatively high p-
values. Nonetheless, most of these compounds were frequently selected during
cross-validation, indicating that they are important for a good discriminant model.
This supports the use of multivariate analysis techniques, in which also the rela-
tionships between compounds are taken into account. In this way, also compounds
that, on their own, do not show a difference between the groups can contribute
greatly to the prediction of S. aureus infection [34].
The current golden standard for detection of S. aureus in CF patients is a
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sputum culture. The reported sensitivity and specificity in adult patients is up
to 100% and 63%, respectively [38]. However, young CF patients are not able to
expectorate adequate samples and therefore upper airway swabs (including throat
swabs) are used for diagnosis. The sensitivity of these swabs varies between 50 -
100%, and the specificity between 23 - 100% [38-42]. In our study, multivariate
breath VOC profiles discriminated S. aureus infected from non-infected CF pa-
tients with a high sensitivity of 100% and a specificity of 80%, and therefore, breath
analysis is an interesting alternative for current detection methods, especially in
patients from whom a sputum sample is not available.
We are aware that five patients without S. aureus infection that were used as
a reference is a relatively low number. However, this is a consequence of the strict
criteria (free from S. aureus infection over the previous 12 months) we used for
inclusion of patients in this group, whereas S. aureus infection is very common in
CF patients. This means, unfortunately, that only a limited number of patients
were free from S. aureus infection, and could be included in this study. Secondly,
CF patients very often have respiratory infections. Therefore, these patients might
be (co-)infected with other pathogens, and we previously showed in an in vitro
study [16] that VOC profiles in co-microbial environment differ from those released
by pathogens in mono-culture. For this reason, the VOCs in exhaled breath of
patients with mixed respiratory infections may be different as well.
In general, breath profiles are influenced by many (confounding) factors which
are difficult to control. For example, diet, medication, and the time of day the
sample is taken. We are aware that the small number of patients included in
this study enlarges the influence of these factors on the difference between patient
groups detected by s-PLS-DA. Also exogenous compounds, such as those present
in ambient air, can be confounding factors. However, we subtracted the compound
concentrations in ambient air from those in exhaled breath to correct for this, as
described by Philips et al. [27]. It is true that this procedure does not take into
account the complexity of gas exchange processes in the lung such as the alveolar
concentration gradients of the substances [43]. However, the best alternative would
be to let participants breathe pure air before they provide a breath sample, which
is time consuming and therefore not suitable for clinical routine measurements
[44]. To reduce the influence of breath-to-breath variability we averaged duplicate
measurements. Furthermore, a strict cross-validation scheme kept the effect of
individual variability to a minimum. This study aimed to determine whether we
can discriminate between S. aureus infected from non-infected CF patients. Yet,
for the identification of specific biomarkers for S. aureus infection larger cohort
studies are needed.
We conclude from this proof of principle study that GC-MS breath VOC pro-
files are promising for detection of S. aureus infections in CF patients and that
s-PLS-DA is a useful tool in such studies. With s-PLS-DA we were able to discrim-
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inate S. aureus infected from non-infected patients with 100% sensitivity and 80%
specificity. We obtained a shortlist of nine important compounds for the detection
of S. aureus that can be used as a focus point in further biomarker identification
research. In addition, this study may inspire and lead to future studies into the
non-invasive detection of others airway infections in CF patients.
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Chapter 6. Summary and future perspectives
In this thesis, we investigated the possibility of using VOCs for the detec-
tion of respiratory pathogens in exhaled breath of CF patients, with the focus on
P. aeruginosa, S. aureus and A. fumigatus. This chapter will discuss the main
findings of our investigations and practical considerations for VOC analysis. Fi-
nally, concluding remarks and future perspectives will be presented.
6.1 Summary
According to the previous literature at the start of this project in 2012, HCN was
a promising biomarker for the detection of P. aeruginosa, and for this reason a
hot topic. Breath HCN was measured for the first time in 1988 by Lundquist et
al. [1] and P. aeruginosa was found to be one of the limited number of bacteria
that produce HCN in vitro [2]. From 2004 on, several in vitro and in vivo studies
reported promising data, showing the potential of HCN as a breath biomarker
for detection of P. aeruginosa. However, to better understand the physiological
mechanisms of HCN production, investigation of the dynamics of HCN release
was needed. We therefore studied the HCN production profiles of both reference
strains and clinical isolates of P. aeruginosa, and assessed the influence of differ-
ent environmental factors (e.g. temperature and media) on the HCN production.
This study revealed for the first time a broad overview of the dynamics of the
HCN production in vitro; HCN production starts to rise as soon as P. aerugi-
nosa bacteria reach the stationary phase, and different strains of P. aeruginosa
produced HCN to varying degrees. Furthermore, this was the first study that in-
vestigated the effect of antibiotic treatment on HCN production by P. aeruginosa;
addition of tobramycin strongly reduced HCN production within 2 h from appli-
cation, indicating that HCN detection can provide a useful tool for monitoring
the effect of antibiotic treatment on P. aeruginosa infection in patients. In paral-
lel with HCN, NH3 production was also monitored in vitro. We found that it is
produced simultaneously, in high quantities, presumably to prevent HCN toxicity
for itself, but the exact mechanism is still unknown. These results contributed to
the existing knowledge about HCN and NH3 production by P. aeruginosa, and
stimulated our interest in this potential biomarker. The next step was to deter-
mine whether HCN was specific for P. aeruginosa, by testing other pathogens
commonly present in lungs/airways of CF patients. So far, besides P. aeruginosa,
only B. cepacia was known to be cyanogenic in vitro, in biofilm cultures [3]. We
tested B. cepacia in our experiments and demonstrated that HCN is produced in
planktonic cultures of B. cepacia as well. Furthermore, S. aureus, from which it
was not known that it could produce HCN, emitted significant levels as well. As-
pergillus fumigatus, Stenotrophomonas maltophilia and Mycobacterium abscessus
did not produce detectable levels. Since investigations into the emission of HCN
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by S. aureus were very limited, we set up a study to assess this. We measured the
real-time HCN production by commercial and clinical S. aureus isolates in vitro,
and HCN levels in exhaled breath of S. aureus infected CF patients, in compar-
ison with non-infected CF patients, as well as healthy persons as controls. This
study demonstrated that HCN is produced by S. aureus in vitro and is present
in exhaled breath of S. aureus infected CF patients. Furthermore, we investi-
gated whether the S. aureus strains cultured from patients in whom HCN was
detected in breath, were capable of producing HCN. We found correlated HCN
levels in vitro and in breath, indicating that the breath HCN levels originate from
S. aureus infection in the lung. This demonstrated that HCN in exhaled breath
is not an exclusive biomarker for P. aeruginosa infection. For this reason, we
started to investigate other VOCs produced by this pathogen, using GC-MS. It
is known that polymicrobial infections are common in CF. But so far, it was un-
known whether VOCs released by mono-cultures are constant or change in the
presence of other pathogens due to e.g. interspecies competition. Therefore, we
assessed VOCs emitted by P. aeruginosa mono-cultures as well as by co-cultures
with A. fumigatus. We took headspace samples at 16, 24 and 48 hours after in-
oculation and found distinct VOCs for mono- and co-cultures at each sampling
time point. Moreover, this study demonstrated that the VOC combinations in
P. aeruginosa and A. fumigatus co-microbial environment are different from those
released by these pathogens in mono-culture. We provided important insight in the
complexity of VOC production by respiratory pathogens and support the use of
co- or polymicrobial cultures in future in vitro studies. Furthermore, it raised the
question whether detection of one respiratory pathogen is feasible when present in
a polymicrobial environment, such as the CF lung, based on assessment of VOCs
in exhaled breath. To investigate this, we selected S. aureus infection, and as-
sessed whether breath profiles could discriminate between S. aureus infected and
non-infected CF patients. The breath VOC profiles successfully discriminated the
two patient groups with a sensitivity and specificity of 100% and 80%, respec-
tively. Additionally, using advanced multivariate data analysis techniques, nine
compounds important for this discrimination could be identified. Those VOCs
can be used as a focus point in further biomarker identification research. Univari-
ate analysis of these nine important compounds indicated undecane as significant,
and its use as a single biomarker to detect S. aureus in breath deserves extra at-
tention. In general, these studies contributed to the existing knowledge on VOC
biomarkers and biomarker profiles, in vitro and in vivo, which is interesting for
future detection of pathogens in exhaled breath of CF patients.
85
6Chapter 6. Summary and future perspectives
6.2 Practical considerations
The analysis of VOCs in biological samples is extremely attractive. However,
in order to perform high quality studies, one needs to consider several practical
issues with regard to the collection, storage and analysis of the samples. In this
paragraph, these practical considerations for VOC analysis will be discussed.
6.2.1 VOC analysis in vitro
A relatively large number of studies have been performed on the in vitro emission of
VOCs by CF related pathogens in order to identify potential biomarkers. However,
unfortunately, among those studies, contradictory results can be found. These
contradictions might be explained by the fact that several research groups perform
headspace analysis according to different protocols and therefore, standardization
is lacking. Factors such as culturing (on solid agar versus in liquid medium) or
flushing the microbial headspace (yes or no), for example, might influence the
VOC production in vitro. Furthermore, multiple strains of the same pathogen can
produce different concentrations of a specific volatile [4-6], and VOC production
in microbial cultures is time dependent [5-9]. The production of VOCs is a result
of metabolic processes inside the pathogen, which is sensitive to many factors.
Because of this, the in vitro VOC production is also dependent on environmental
conditions such as nutrient availability [10]. Since BHI broth medium is a rich
and animal derived medium, which is more comparable to the human lung than
synthetic media, we selected this medium for culturing the bacteria in all our
studies. However, it is unknown whether the in vitro VOC production of bacteria
cultured in BHI medium is comparable to the in vivo production in the lung.
Additionally, temperature and antibiotic treatment influence VOC production.
6.2.2 VOC analysis in breath
Breath sampling methods
It is generally presumed that it is critical to standardize the breath sampling
procedure, since differences in exhalation manoeuvres can affect the VOC content
in exhaled breath [11, 12]. However, today, there is still no consensus regarding one
unified procedure for collection of a breath sample. Different research groups apply
different methodologies (e.g. sampling at a specific expiration flow rate vs free
exhalation, or the collection of whole breath vs. the alveolar fraction), hindering
the comparison of data. In order to standardize the way a person exhales, different
devices can be used to control exhalation flow rate. For some VOCs it is known
that they are influenced by the speed of exhalation, such as nitric oxide (NO),
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which is elevated in exhaled breath of asthma patients and highly dependent on
the expiratory flow rate [13, 14]. Compared to a high flow rate, NO values are
higher in exhaled breath at a low flow speed. For a single biomarker, like NO, this
flow-dependency can be easily tested. However, if multiple VOCs are detected in
one sample at the same time (such as with GC-MS), this is a complex procedure.
Still, in a study by Incalzi et al. [15], it was found that VOC patterns of chronic
obstructive pulmonary disease patients, strictly correlate with expiration flow.
Therefore, standardisation of exhalation flow speed in breath studies is highly
recommended. In our studies, a commercially available breath sampler was used
in order to minimize the effects of expiratory flow rate on differences in VOCs
in the samples. Since this device is (only) suitable for children who are able to
control their exhalation speed, according to the given instructions, only children
who were 6 years or older, could be included in our studies. In order to sample
breath from babies and pre-schoolers, other sampling methods need to be used.
Another aspect of breath sampling to consider is whether or not to include
dead space gas in the sample. Dead space gas (approximately 2 mL/kg) originates
from the area in the trachea, bronchi, and air passages, which are not involved
in gas exchange in the alveoli. Because of this, this gas typically contains lower
concentrations of CO2 and endogenous VOCs [16]. The dead space gas and the
alveolar gas (originating from the lower airways) together form the whole breath
(see figure 6.1).
Since there is no gas exchange in the dead space, this part of the breath is less
concentrated and therefore dilutes the whole breath sample. For this reason, one
might want to exclude it. Different solutions are reported to exclude the dead space
gas from the alveolar gas [12, 16]. One is the use of a separate small bag which is
filled with the first part of the exhalation, prior to the collection of the alveolar gas
in a bigger bag. In this thesis, we used a small bag with a standard volume of 150
mL to exclude the dead space gas for the breath sample. Another solution is the use
of a CO2 controlled valve. This valve ensures inclusion of only the alveolar exhaled
gas after reaching a CO2 threshold (typically 3.5 % CO2). As soon as the threshold
is reached, the valve will switch and alveolar gas is collected into the sampling bag.
If the CO2 concentration is <3.5% (dead space gas), the device will not collect
gas. Another advantage of determination of CO2 concentrations in breath is the
possibility to correct for varying breathing patterns of different subjects, which
results in variations of the compound concentration. In other words; the CO2
concentration provides information about which part of the exhalation is included
in the sample. When the expired CO2 reaches a plateau, the concentrations of
endogenous VOCs will also reach maximum levels. However, CF patients have
a reduced long function and, for this reason, can have difficulties with exhaling
at one controlled flow speed. Also the collection of one single exhalation from
young children was sometimes difficult. To control for differences in exhalation
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Figure 6.1: Schematic drawing of carbon dioxide (CO2) concentration during normal
exhalation and typical sampling modes (whole breath sampling vs alveolar gas sampling).
between the different participants, we normalized the exhaled HCN levels to the
CO2 concentration in the samples.
Other factors that might generate variability in exhaled breath samples are
breath hold prior to exhalation [17, 18] and the number of exhalations (single
or multiple exhalations) in one sample. However, studies investigating the exact
effects of the number of exhalations have not been published, yet. For techniques
requiring preconcentration (like GC-MS), bigger volumes increase the sensitivity of
the system. For this reason, multiple exhalations are favourable and therefore, two
exhalations are collected in one 3L bag, in our study. However, to further increase
sensitivity, collecting even bigger volumes can be favourable. For this purpose, a
Respiration Collector for In Vitro Analysis (ReCIVA) breath sampler has recently
been developed by Owlstone Inc. Using this sampler, in which patients can breathe
freely, selected volumes and fractions of exhaled breath VOCs can be collected on
sorbent packed tubes for analysis. Whether VOCs in samples of one or multiple
exhalations will differ qualitatively and quantitatively from each other, has to be
determined in future studies.
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Breath sampling methods
In order to collect a breath sample which can be transported to the analytical in-
strument, sampling bags need to be used. Multiple types of bags are currently on
the market, all having their own advantages and disadvantages. Different aspects
are important to consider when selecting a suitable bag for collecting breath sam-
ples. Firstly, the bag material should contaminate the samples as little as possible.
Secondly, VOCs should not stick to the bag material, and finally, the compounds
of interest should be stable in the bag material. In our studies, polyvinyl fluoride
(PVF); tradename Tedlar, was used. Tedlar is most frequently used for collection
of breath samples, since the samples are stable for a minimum of 10 hours and the
bags can be re-used after cleaning the bags according to a specific cleaning protocol
[19]. However, Tedlar is known to release phenol and N,N-dimethylacetamide [20].
Signals deriving from these compounds need to be removed before data analysis.
The stability of HCN in multiple bag materials has been studied by Gilchrist et
al. [21]. In Tedlar and 70 µm Nalophan bags, HCN was found to be stable up to
24 hours. In our studies, all breath samples were analysed using laser-based pho-
toacoustic spectroscopy, or sampled on Tenax tubes for GC-MS analysis, within 8
hours in order to prevent the loss of compounds in the sample.
Preconcentration on sorbent tubes
For some analytical techniques, sample preconcentration is necessary. Different
adsorbent materials are used with regards to preconcentration of breath samples
of which Tenax TA and Carbograph are most common. In our studies, Tenax TA
packed in glass tubes were used since it can trap a wide range of compounds. Cur-
rently, even multibed sorbent tubes are available in which both Carbograph (C3
to C5 region) and Tenax TA (C7 to C30 region), for example, can be combined
for optimal performance. The performance of these sorbent tubes are not only
determined by the range of compounds that can be trapped, but also by break-
through volume (the volume of carrier gas per gram of absorbent which transfer
the VOCs from the front to the back of the absorbent bed), and sampling flow
rate. Since each compound has its own breakthrough volume, determination of
this volume of multiple compounds is rather complex. A study performed by Gal-
lego et al. [22] determined breakthrough volumes of both Tenax TA and multi
sorbent bed (Carbotrap, Carbopack X, Carboxen 569) tubes. High breakthrough
volumes were found for Tenax TA, meaning that compounds are easily transferred
through the sorbent bed, without trapping. Different volumes were tested and at
the lowest volume (10 L), high breakthrough was already detected. In this thesis,
a maximum of 3.5 L was sampled on the Tenax TA tubes, which is far below the
10 L tested in the study described above. Aditionally, as mentioned above, also
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the sampling flow rate significantly influences the breakthrough volume of mul-
tiple compounds using Tenax TA tubes [22]. Since lower breakthrough volumes
were found for increasing sampling rates (4.2 vs. 5.4 L/h), the experiments in this
thesis were performed using a relatively low sampling rate (3 - 3.5 L/h).
Ambient air
Exogenous compounds, such as those present in ambient air, can be confounding
factors in breath analysis. Because of this, correcting for compounds in ambient
air might be mandatory for statistical analysis [16]. However, how to correct for
this is still under debate. Correcting exhaled concentrations by subtracting inspi-
ratory from expiratory concentrations, called alveolar gradients is one possibility
[23]. However, this procedure does not take into account the complexity of gas
exchange processes in the lung such as the alveolar concentration gradients of the
substances [24]. Others suggest to exclude compounds having inspired concen-
trations more than a specified percentage (f.e. 5 %) of expired concentrations as
breath markers [25]. Another solution is letting participants to breathe purified
air from high-pressure gas cylinders, for a certain time, before breath collection
[26]. This approach is effective but time consuming and not suitable for clinical
routine measurements. In our studies using GC-MS, we therefore calculated alve-
olar gradients. Since HCN is not normally present in ambient air (levels below
detection limit), correction for HCN background levels was not necessary.
Other factors influencing breath
Many external factors can influence the compounds in exhaled breath such as
physical activity, use of medicines, and food intake [27-29]. Hydrogen cyanide,
for example, is present in various fruit seeds, cassava and flax seeds [30]. The
effect of HCN containing food products on HCN exhaled breath has never been
investigated. However, in our studies, food intake (2 hour prior to breath sampling)
was reported and patients who ate the above mention products were excluded.
Furthermore, cigarette smoke contains HCN [31]. For this reason, smokers were
excluded from this thesis as well.
6.3 Concluding remarks and future perspectives
From this thesis, it can be concluded that HCN in exhaled breath is not an exclu-
sive biomarker for P. aeruginosa infection, which is a significant drawback in the
attempt to develop a non-invasive method to detect P. aeruginosa in patients with
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Table 6.1: Recommendations for further research.
1. Online or at least high resolution measurements to study VOC patterns
in detail.
2. A standardized protocol for breath sampling.
3. In vitro vs. in vivo correlation studies to determine the potential of
VOCs for detection of pathogens in breath.
4. Combination of off-line techniques such as GC-MS, for the identification
of potential biomarkers, with online methods, to study those specific
VOCs in a detailed manner.
5. Larger cohort studies to confirm and validate potential biomarkers.
CF. However, breath analysis has still potential to diagnose lung infections. Al-
though, in vitro, the VOCs in co-microbial environment differ from those released
in mono-culture, patients with S. aureus (present in a polymicrobial environment)
can be successfully discriminated from CF patients without S. aureus. However,
future studies are needed in order to investigate which biomarker(s) are most suit-
able for this purpose. Recommendations for further research will be discussed in
this paragraph and are summarized in table 6.1.
The ideal biomarker is constantly produced by the pathogen, at equal concen-
trations, in different growth phases. However, current data suggest that this is not
necessarily realistic. Therefore, online- or at least high resolution measurements,
like performed in this thesis using laser-based photo-acoustic spectroscopy, are de-
sirable to better understand the production pattern of VOCs by pathogens. This
knowledge can then be used to determine whether a certain VOC has potential
for early detection of pathogens in exhaled breath. Secondly, a more standardized
protocol for breath sampling is really needed in order to compare data obtained
in different studies. This protocol ideally includes exhalation at a controlled flow
speed or normal free breathing, and excludes the dead space volume. Moreover,
analysis of CO2 concentration of these samples is desirable. Thirdly, it would be
very interesting to further explore the correlation between in vitro and in vivo
VOC production by analysing breath, the headspace of sputum of CF patients
obtained on the day of breath sampling, and the headspace of bacterial cultures
isolated from that sputum. This will provide more insight in the suitability of in
vitro identified biomarkers. Another future possibility is to combine different tech-
niques in order to study specific VOCs in a detailed manner. Combining off-line
techniques such as GC-MS, for the identification of potential biomarkers, with on-
line methods (such as laser-based methods, PTR-MS or SIFT-MS) to study those
compounds in further detail. Additionally, high sensitivity and high resolution
accurate mass data, such as obtained with GC-TOF-MS, can further improve the
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detection of VOCs in breath. Finally, large cohort studies are necessary in order to
confirm and validate the compounds that are currently proposed as biomarkers for
different respiratory infections. These studies should show whether early detection
and even monitoring of respiratory infections in exhaled breath of CF patients is
ready for clinical practise. If that is the case, this non-invasive technique has also
great potential for application in the diagnosis of pneumonia and other infectious
diseases, lung diseases, and even diseases in other medical fields. To successfully
perform high quality breath analysis studies to investigate this, a multidisciplinary
research team in which trace gas researchers, medical doctors, technical experts,
and statisticians collaborate, is vital.
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Taaislijmziekte of cystic fibrosis (CF) is de meest voorkomende ongenees-
lijke erfelijke aandoening. Een defect in het Cystic Fibrosis Transmembrane
conductance Regulator (CFTR)-gen leidt onder andere tot een verstoord zout-
watertransport, waardoor taai slijm ontstaat. Dit taaie slijm geeft voornamelijk
problemen in de longen; het is een voedingsbodem voor bacterie¨n en ophoesten
ervan is lastig. Hierdoor blijven bacterie¨n aanwezig in de long en dit zorgt voor
chronische infecties, ontsteking en vorming van littekenweefsel wat uiteindelijk
een sterke vermindering van de longfunctie tot gevolg heeft. Om luchtweginfec-
ties goed te kunnen behandelen, is het belangrijk dat deze in een vroeg stadium
worden vastgesteld. De huidige gouden standaard om luchtweginfecties te kunnen
detecteren is de zogenoemde sputumkweek. Echter, jonge CF patie¨nten kunnen
vaak geen adequaat slijmmonster ophoesten en beschikbare alternatieven zijn in-
vasief (bronchoscopie), volkomen aspecifiek (longfoto) of onbetrouwbaar (hoest-
wat). Een snelle, patie¨ntvriendelijke, betrouwbare, veilige en gevoelige methode
om luchtweginfecties in een vroeg stadium te diagnosticeren is daarom dringend
nodig. De analyse van gassen, geproduceerd door bacterie¨n die de luchtweginfectie
veroorzaken, in expiratiegas is hiervoor zeer interessant.
Waterstofcyanide (HCN) werd beschreven als een veelbelovende biomarker
voor e´e´n van de belangrijkste bacterie¨n in CF; Pseudomonas aeruginosa (P. ae-
ruginosa). Om deze reden is HCN veel bestudeerd. In adem werd HCN voor
het eerst gedetecteerd in 1988 door Lundquist et al. en P. aeruginosa werd vast-
gesteld als een van de weinige bacterie¨n die in vitro HCN produceerde. Vanaf
2004 rapporteerden verschillende in vitro en in vivo studies veelbelovende data,
die de potentie van HCN als biomarker voor de detectie van P. aeruginosa in
adem demonstreerden. Echter, om de fysiologische mechanismen achter de pro-
ductie van HCN beter te begrijpen, was het nodig om de HCN-productiedynamiek
te onderzoeken. Om deze reden bestudeerden wij de HCN-productieprofielen van
zowel referentiestammen als klinische isolaten van P. aeruginosa. Tevens hebben
we de invloed van omgevingsfactoren (temperatuur en medium) op de productie
van HCN onderzocht. Deze studie gaf voor het eerst een breed overzicht van de
dynamiek van HCN-productie in vitro; de productie van HCN start wanneer P. ae-
ruginosa bacterie¨n de stationaire groeifase bereiken en verscheidene P. aeruginosa
stammen produceren HCN in verschillende mate. Daarnaast was dit de eerste
studie die het effect van antibioticabehandeling op de productie van HCN door
P. aeruginosa bestudeerde; toevoeging van Tobramycine vermindert binnen 2 uur
sterk de HCN-productie, wat aangeeft dat HCN-detectie mogelijk gebruikt kan
worden om het effect van antibioticabehandeling op infectie met P. aeruginosa in
patie¨nten te monitoren. Parallel aan HCN werd ook ammoniak (NH3)-productie
in vitro onderzocht. We vonden dat NH3 tegelijk met HCN geproduceerd wordt, in
hoge concentraties, mogelijk om HCN-toxiciteit voor de bacterie zelf te voorkomen
maar het exacte mechanisme hiervan is onbekend. Deze resultaten hebben bijge-
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en stimuleerde onze interesse in deze potentie¨le biomarker.
De volgende stap was om vast te stellen of HCN specifiek was voor P. aerugin-
osa, door ook andere veelvoorkomende CF pathogenen te testen. Tot zover was er
naast P. aeruginosa, alleen van Burkholderia cepacia (B. cepacia) bekend dat deze
bacterie in in vitro biofilmkweken HCN kon produceren. We hebben B. cepacia
ook in onze experimenten getest en konden aantonen dat HCN eveneens in plank-
tonkweken wordt geproduceerd. Daarnaast bleek dat ook Staphylococcus aureus
(S. aureus), waarvan nog niet bekend was of deze bacterie HCN kon produceren,
significante hoeveelheden kan produceren. Aspergillus fumigatus (A. fumigatus),
Stenotrophomonas maltophilia en Mycobacterium abscessus produceerden geen de-
tecteerbare waarden. Aangezien onderzoek naar HCN-emissie door S. aureus tot
dusver heel beperkt was, hebben we de HCN-productie hiervan in meer detail be-
studeerd. We hebben succesvol de HCN-productie gemeten van commercie¨le- en
klinische S. aureus-isolaten in vitro, en ook de HCN-concentratie in expiratiegas
van CF patie¨nten, met niet-ge¨ınfecteerde CF patie¨nten en gezonde personen als
controles. Deze studie liet zien dat HCN geproduceerd wordt door S. aureus in
vitro en aanwezig is in expiratiegas van CF patie¨nten ge¨ınfecteerd met S. aureus.
Daarnaast onderzochten we of de S. aureus stammen, aanwezig in de sputumkweek
van diezelfde patie¨nten met verhoogde HCN-waarden in expiratiegas in vitro HCN
konden produceren. We vonden een correlatie tussen de HCN-waarden in vitro en
in vivo wat aangeeft dat de HCN-waarden in adem afkomstig zijn van S. aureus-
infectie in de long. Dit vormt het bewijs dat HCN in expiratiegas geen exclusieve
biomarker is voor P. aeruginosa infectie.
Om deze reden zijn we gestart met het onderzoeken van de productie van
andere vluchtige organische componenten (VOCs) die geproduceerd worden door
P. aeruginosa, met behulp van gas chromatografie gecombineerd met massa spec-
trometrie (GC-MS). Het is bekend dat polymicrobie¨le infecties veel voorkomend
zijn in CF. Alleen was het tot dusver nog onbekend of de VOCs die geproduceerd
worden door in vitro monoculturen, constant zijn of varie¨ren in de aanwezigheid
van andere pathogenen, bijvoorbeeld door competitie om ruimte en/of nutrie¨nten
tussen de species. Daarom hebben we de VOCs die geproduceerd worden door
zowel monoculturen van P. aeruginosa, monoculturen van A. fumigatus, als cocul-
turen van deze pathogenen onderzocht. We namen 16, 24 en 48 uur na inoculatie
monsters van de lucht boven de kweken en detecteerden onderscheidende VOCs
voor de mono- en coculturen op de verschillende tijdspunten. Ook liet deze studie
zien dat de VOC-combinaties in een cocultuur verschillend zijn van de combi-
naties die door deze pathogenen in monocultuur worden geproduceerd. Hiermee
hebben wij belangrijk inzicht verkregen in de complexiteit van de VOC-productie
door respiratoire pathogenen, wat het gebruik van co- of polymicrobie¨le kweken in
toekomstige in vitro studies ondersteunt.
99
7Hoofdstuk 7. Samenvatting
Deze resultaten waren aanleiding om ons af te vragen of de detectie van een
enkele pathogeen op basis van ademanalyse mogelijk is, wanneer deze aanwezig is
in een in vivo polymicrobie¨le omgeving, zoals de CF-long. Om dit vast te stel-
len, onderzochten we of ademprofielen van CF-patie¨nten ge¨ınfecteerd met S. aureus
kunnen worden onderscheiden van CF-patie¨nten die niet ge¨ınfecteerd zijn met deze
bacterie. De VOC-profielen in adem discrimineerde deze twee patie¨ntgroepen met
een sensitiviteit en specificiteit van respectievelijk 100 en 80%. Met behulp van
geavanceerde multivariate data-analyse technieken konden er negen componenten
worden ge¨ıdentificeerd die belangrijk zijn voor deze discriminatie. Deze VOCs
kunnen als focuspunt in verder biomarkeronderzoek worden gebruikt. Univariate
analyse van deze negen componenten duidde undecaan aan als significant en hier-
door verdient het gebruik van deze stof als individuele biomarker voor S. aureus
in adem extra aandacht in de toekomst.
Op basis van dit proefschrift kan geconcludeerd worden dat HCN in uitade-
minglucht geen exclusieve biomarker is voor P. aeruginosa infectie. Dit is een
wezenlijke tegenslag voor de poging om een niet-invasieve methode te ontwikkelen
om specifiek infecties met P. aeruginosa te detecteren in CF-patie¨nten. Echter,
dit onderzoek heeft laten zien dat twee belangrijke pathogenen in CF-patie¨nten
in staat zijn om HCN te produceren. Daarom zal de aanwezigheid van HCN in
expiratiegas een aanleiding kunnen zijn tot het aanpassen dan wel starten van
een antibiotische therapie. Ondanks dat VOCs in vitro in een comicrobie¨le omge-
ving verschillen van de VOCs die geproduceerd worden in monoculturen, kunnen
patie¨nten met S. aureus (aanwezig in de polymicrobie¨le longen) succesvol worden
onderscheiden van CF-patie¨nten zonder S. aureus-infectie. Toekomstige studies
zijn nodig om vast te stellen welke biomarkers het meest geschikt zijn voor dit
doel. Ademanalyse heeft de potentie om bacterie¨le luchtweginfecties te diagnosti-
ceren maar het onderzoek naar de mogelijkheden is in feite pas recent gestart.
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